{"efta_number": "EFTA00617635", "page_count": 74, "url": "https://epstein-data.com/EFTA00617635", "pdf_url": "https://epstein-data.com/pdf/EFTA00617635.pdf", "pages": [{"efta_number": "EFTA00617635", "page_number": 0, "text_content": "DRAFT DATED 9/17/14 \nCopy No. \nBIOSYS CAPITAL PARTNERS, \nLP \nConfidential Private Placement Memorandum \nSeptember __, 2014 \nSTRICTLY CONFIDENTIAL \nDRAFT - Jeffery Epstein \nEFTA00617635\n", "char_count": 185}, {"efta_number": "EFTA00617635", "page_number": 1, "text_content": "THE LIMITED PARTNERSHIP INTERESTS IN THE FUND DESCRIBED HEREIN (THE \n\"INTERESTS\") HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT \nOF 1933, AS AMENDED (THE \"SECURITIES ACT') OF THE UNITED STATES OF AMERICA (THE \n\"U.S.\") OR THE SECURITIES LAWS OF ANY OTHER COUNTRY OR JURISDICTION. THE ISSUER \nIS RELYING ON EXEMPTIONS FROM SUCH REGISTRATION OR QUALIFICATION. INVESTORS \nMAY BE REQUIRED TO HOLD THE INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. \nOTHER IMPORTANT RISK FACTORS ARE EXPLAINED IN DETAIL IN THIS DOCUMENT. NO \nGOVERNMENTAL \nAUTHORITY \nHAS \nAPPROVED, \nDISAPPROVED, \nENDORSED, \nOR \nRECOMMENDED THIS OFFERING. \nNO INDEPENDENT PERSON HAS CONFIRMED THE \nACCURACY OR TRUTHFULNESS OF THIS DISCLOSURE, NOR WHETHER IT IS COMPLETE. \nANY REPRESENTATION TO THE CONTRARY IS ILLEGAL. SEE APPENDIX A - \nCERTAIN \nSECURITIES LAW MATTERS FOR INVESTORS. \nTHIS CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM (THIS \"MEMORANDUM\") DOES \nNOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY THE \nINTERESTS AS TO ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL TO MAKE \nSUCH AN OFFER OR SOLICITATION. WITHIN THE U.S. THIS OFFERING IS MADE AS A PRIVATE \nPLACEMENT PURSUANT TO SECTION 4(2) OF THE SECURITIES ACT, AND ONLY TO PARTIES \nTHAT ARE \"ACCREDITED INVESTORS\" AS DEFINED IN RULE 501(A) OF REGULATION D \nUNDER THE SECURITIES ACT. OUTSIDE THE U.S., THIS OFFERING IS MADE PURSUANT TO \nREGULATION S UNDER THE SECURITIES ACT, ONLY TO PARTIES THAT ARE NOT \"U.S. \nPERSONS\" AS DEFINED IN SUCH REGULATION, AND PURSUANT TO EXEMPTIONS FROM \nAPPLICABLE SECURITIES LAWS OF OTHER COUNTRIES (\"NON-U.S. SECURITIES LAWS\"). SEE \nAPPENDIX A - CERTAIN SECURITIES LAW MATTERS FOR INVESTORS. \nTHIS MEMORANDUM IS NOT A PROSPECTUS OR AN ADVERTISEMENT, AND THE OFFERING \nIS NOT BEING MADE TO THE PUBLIC. \nTHIS OFFERING IS MADE IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION \nREQUIREMENTS OF THE SECURITIES ACT AND NON-U.S. SECURITIES LAWS AS DESCRIBED \nABOVE. \nTHE FUND DOES NOT INTEND TO REGISTER THE\n... [truncated, 3688 chars — for the full page use /api/corpus/document/EFTA00617635/1 or ?id=EFTA00617635&page=1]", "char_count": 3688}, {"efta_number": "EFTA00617635", "page_number": 2, "text_content": "BY LEGAL COUNSEL. EACH PROSPECTIVE INVESTOR IS RESPONSIBLE FOR ITS OWN COSTS \nIN CONSIDERING AN INVESTMENT IN AN INTEREST. NEITHER THE GENERAL PARTNER NOR \nTHE FUND SHALL HAVE ANY LIABILITY TO A PROSPECTIVE INVESTOR WHOSE \nSUBSCRIPTION IS REJECTED IN WHOLE OR IN PART. \nTHE INFORMATION SET FORTH IN THIS MEMORANDUM IS CONFIDENTIAL AND INCLUDES \nTRADE SECRETS THE DISCLOSURE OF WHICH WOULD CAUSE HARM TO THE FUND, THE \nGENERAL PARTNER AND OTHER PARTIES. \nRECEIPT AND ACCEPTANCE OF THIS \nMEMORANDUM SHALL CONSTITUTE AN AGREEMENT BY THE RECIPIENT THAT THIS \nMEMORANDUM SHALL NOT BE REPRODUCED OR USED FOR ANY PURPOSE OTHER THAN IN \nCONNECTION WITH THE RECIPIENT'S EVALUATION OF AN INVESTMENT IN AN INTEREST. \nTHIS MEMORANDUM IS THE PROPERTY OF THE GENERAL PARTNER AND, EXCEPT AS HELD \nBY A LIMITED PARTNER OF THE FUND, MUST BE RETURNED UPON REQUEST. \nNO PERSON HAS BEEN AUTHORIZED TO MAKE ANY REPRESENTATIONS OR TO GIVE ANY \nINFORMATION WITH RESPECT TO THE FUND, THE GENERAL PARTNER, OR THE INTERESTS, \nOTHER THAN AS CONTAINED IN THIS MEMORANDUM, THE FUND'S AGREEMENT OF \nLIMITED \nPARTNERSHIP \n(THE \n\"PARTNERSHIP \nAGREEMENT'), THE \nSUBSCRIPTION \nAGREEMENT TO BE EXECUTED BY EACH INVESTOR, OR AN OFFICIAL WRITTEN \nSUPPLEMENT TO THIS MEMORANDUM APPROVED BY THE GENERAL PARTNER. \nPROSPECTIVE INVESTORS ARE CAUTIONED AGAINST RELYING UPON INFORMATION OR \nREPRESENTATIONS FROM ANY OTHER SOURCE. NOTWITHSTANDING THE FOREGOING, A \nPROSPECTIVE INVESTOR MAY RELY UPON WRITTEN RESPONSES TO ITS INQUIRIES THAT \nARE CLEARLY MARKED BY AN OFFICER OF THE GENERAL PARTNER AS INTENDED TO BE \nRELIED UPON BY SUCH PROSPECTIVE INVESTOR. \nPROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THIS MEMORANDUM AS INVESTMENT, \nLEGAL OR TAX ADVICE AND THIS MEMORANDUM IS NOT INTENDED TO PROVIDE THE SOLE \nBASIS FOR ANY EVALUATION OF AN INVESTMENT IN AN INTEREST. PRIOR TO ACQUIRING \nAN INTEREST, A PROSPECTIVE INVESTOR SHOULD CONSULT WITH ITS OWN LEGAL, \nINVESTMENT, TAX, ACCOUNTING, AND OTHER ADVISORS TO DETERMINE THE POTENTIAL \nBENEFITS,\n... [truncated, 3685 chars — for the full page use /api/corpus/document/EFTA00617635/2 or ?id=EFTA00617635&page=2]", "char_count": 3685}, {"efta_number": "EFTA00617635", "page_number": 3, "text_content": "EXCEPT WHERE OTHERWISE SPECIFICALLY INDICATED, THIS MEMORANDUM SPEAKS AS \nOF THE DATE HEREOF. NEITHER THE SUBSEQUENT DELIVERY OF THIS MEMORANDUM NOR \nANY SALE OF INTERESTS SHALL BE DEEMED A REPRESENTATION THAT THERE HAS BEEN \nNO CHANGE IN THE AFFAIRS, PROSPECTS OR ATTRIBUTES OF THE FUND SINCE THE DATE \nHEREOF. ALL DUTIES TO UPDATE THIS MEMORANDUM ARE HEREBY DISCLAIMED. EXCEPT \nAS EXPRESSLY STATED TO THE CONTRARY THEREIN, ANY OFFICIAL SUPPLEMENT OR \nUPDATE TO THIS MEMORANDUM SHALL BE DEEMED TO ADDRESS ONLY THE SPECIFIC \nSUBJECT MATTER THEREOF AND SHALL NOT BE DEEMED A REPRESENTATION THAT THERE \nHAS BEEN NO OTHER CHANGE IN THE AFFAIRS, PROSPECTS OR ATTRIBUTES OF THE FUND \nSINCE THE DATE HEREOF. \nTHIS MEMORANDUM SUPERSEDES ALL PRIOR VERSIONS. FROM AND AFTER THE DATE OF \nTHIS MEMORANDUM, PRIOR VERSIONS OF THIS MEMORANDUM MAY NOT BE RELIED UPON. \nNOTHING CONTAINED HEREIN IS, OR SHOULD BE RELIED UPON AS, A PROMISE OR \nREPRESENTATION AS TO THE FUTURE PERFORMANCE OF THE FUND. \nSTATEMENTS, \nESTIMATES, TARGETS AND PROJECTIONS WITH RESPECT TO SUCH FUTURE PERFORMANCE \nSET FORTH IN THIS MEMORANDUM ARE BASED UPON ASSUMPTIONS MADE BY THE \nGENERAL PARTNER WHICH MAY OR MAY NOT PROVE TO BE CORRECT. \nNO \nREPRESENTATION IS MADE AS TO THE ACCURACY OF SUCH STATEMENTS, ESTIMATES, \nTARGETS AND PROJECTIONS. SIMILARLY, NOTHING CONTAINED HEREIN IS, OR SHOULD \nBE RELIED UPON AS, A PROMISE OR REPRESENTATION AS TO THE EXTERNAL CONDITIONS \nAND CIRCUMSTANCES UNDER WHICH THE FUND WILL OPERATE (INCLUDING, WITHOUT \nLIMITATION, OVERALL MARKET CONDITIONS, TECHNOLOGY DEVELOPMENTS AND OTHER \nMATTERS OUTSIDE THE CONTROL OF THE GENERAL PARTNER). OVERALL, PROSPECTIVE \nINVESTORS MUST NOT RELY UPON ANY MATTERS DESCRIBED IN THIS MEMORANDUM \nTHAT ARE NOT WHOLLY WITHIN THE CONTROL OF THE GENERAL PARTNER. EVEN WITH \nREGARD TO MATTERS WHOLLY WITHIN THE CONTROL OF THE GENERAL PARTNER, THE \nACTIVITIES UNDERTAKEN BY THE GENERAL PARTNER IN MANAGING THE FUND MAY \nDIFFER FROM THOSE DESCRIBED IN THIS MEMORANDUM DUE TO UN\n... [truncated, 3436 chars — for the full page use /api/corpus/document/EFTA00617635/3 or ?id=EFTA00617635&page=3]", "char_count": 3436}, {"efta_number": "EFTA00617635", "page_number": 4, "text_content": "MEANING OF SECTION 27A OF THE SECURITIES ACT. THESE STATEMENTS INCLUDE \nTHE PLANS AND OBJECTIVES OF MANAGEMENT FOR FUTURE OPERATIONS, \nINCLUDING PLANS AND OBJECTIVES RELATING TO FUTURE GROWTH OF THE FUND. \nTHE FORWARD-LOOKING STATEMENTS INCLUDED HEREIN ARE BASED ON CURRENT \nEXPECTATIONS THAT INVOLVE NUMEROUS RISKS AND UNCERTAINTIES IDENTIFIED \nIN THIS MEMORANDUM. ASSUMPTIONS RELATING TO THE FOREGOING INVOLVE \nJUDGMENTS WITH RESPECT TO, AMONG OTHER THINGS, FUTURE ECONOMIC, \nCOMPETITIVE AND MARKET CONDITIONS AND FUTURE BUSINESS DECISIONS, ALL OF \nWHICH ARE DIFFICULT OR IMPOSSIBLE TO PREDICT ACCURATELY AND MANY OF \nWHICH ARE BEYOND THE FUND'S CONTROL. ALTHOUGH THE FUND BELIEVES THAT \nTHE ASSUMPTIONS UNDERLYING THE FORWARD-LOOKING STATEMENTS ARE \nREASONABLE, ANY OF THE ASSUMPTIONS COULD BE INACCURATE AND, THEREFORE, \nTHERE CAN BE NO ASSURANCE THAT THE FORWARD-LOOKING STATEMENTS \nINCLUDED IN THIS MEMORANDUM WILL PROVE TO BE ACCURATE. IN LIGHT OF THE \nSIGNIFICANT UNCERTAINTIES INHERENT IN THE FORWARD-LOOKING STATEMENTS \nINCLUDED HEREIN, THE INCLUSION OF SUCH INFORMATION SHOULD NOT BE \nREGARDED AS A REPRESENTATION BY THE FUND OR ANY OTHER PERSON THAT THE \nFUND'S OBJECTIVES AND PROJECTIONS WILL BE ACHIEVED. \nSTRICTLY CONFIDENTIAL \niv \nDRAFT - Jeffery Epstein \nEFTA00617639\n", "char_count": 1285}, {"efta_number": "EFTA00617635", "page_number": 5, "text_content": "TABLE OF CONTENTS \nI. EXECUTIVE SUMMARY \n2 \nIL MARKET OPPORTUNITY AND ENVIRONMENT \n4 \nIII. INVESTMENT STRATEGY \n15 \nIV. INVESTMENT PROCESS \n 17 \nV. INVESTMENT COMMITTEE \n19 \nVI. SUMMARY OF PRINCIPAL TERMS OF THE FUND \n23 \nVII. CERTAIN INVESTMENT CONSIDERATIONS AND RISK FACTORS \n34 \nVIII. CERTAIN TAX AND ERISA CONSIDERATIONS \n54 \nIX. ADDITIONAL INFORMATION \n64 \nAppendix A — Certain Securities Law Matters for Investors \nDRAFT - Jeffery Epstein \nEFTA00617640\n", "char_count": 460}, {"efta_number": "EFTA00617635", "page_number": 6, "text_content": "Copy No. \nI. EXECUTIVE SUMMARY' \nBiosys Capital Partners, LP (the \"Fund\" or \"Biosys\") is a venture capital fund formed to make non-\ncontrolling investments in growth-stage companies in the healthcare and life sciences sectors. The \nFund combines the investment experience of Boris Nikolic in the technology and healthcare sectors \nwith several anticipated unique features, including: \n• \nAccess to a broad network of scientists within universities such as Harvard, Stanford and MIT. \n• \nAccess to industry experts and venture capitalists including, for example, close cooperative \nrelationships with Khosla Ventures and ARCH Venture Partners. \n• \nSupport from Bill Gates, who we expect to be a significant investor through associated entities \nwhich have already provided funding for the first warehoused investment of Biosys. \nThe Fund is offering its limited partnership interests for investment. \nThe minimum capital \ncommitment is $10 million, subject to the right of the General Partner (as hereinafter defined) to waive \nthis minimum for qualified investors. Subject to the right of the Fund to extend this offering, this \noffering will terminate eighteen (18) months from the date of the initial closing of the Fund, or on such \nearlier date as all of the limited partnership interests offered hereby are sold. \nThe Fund has invested and intends to continue investing primarily in private companies at the \nintersection of technology and life sciences and does not plan to invest in traditional drug-discovery, \ndiagnostic, and medical-device companies. \nAt $7 trillion, health care represents one of the largest segments of global GDP. In the United States, \nhealth care is a $2.8 trillion industry, comprising 17 percent of GDP, and one that continues to face \ntremendous challenges. Expenditures have grown at an unsustainable rate of 3.5 times GDP growth \nsince 1960, yet these high healthcare expenditures have not led to better outcomes when compared to \nother developed countries. There\n... [truncated, 3278 chars — for the full page use /api/corpus/document/EFTA00617635/6 or ?id=EFTA00617635&page=6]", "char_count": 3278}, {"efta_number": "EFTA00617635", "page_number": 7, "text_content": "DNA sequencing, estimates a $20 billion addressable market for sequencing technology and \napplications. McKinsey & Company estimates that genomics will have an economic impact of \nup to $1.6 trillion on global GDP by 2025. \n• \nSmart sensors and remote-monitoring technologies that enable health and disease \nmanagement as well as efficient healthcare delivery. In 2013, 45 million health-and-fitness-\noriented wearable devices were shipped, and mobile health is already an $8 billion market. \n170 million health-and-fitness-oriented devices are expected to be shipped in 2017, and the \nglobal mobile health market is expected to be worth $59 billion by 2020. This is an opportunity \nnot just for consumer-oriented devices but also for transformative technologies for monitoring \npatients and practicing medicine. \n• \nDigitization of medical records, as well as other investment in healthcare information \ntechnology (IT), that enables the development of new digital-health platforms. More than 50 \npercent of doctors' offices and 80 percent of hospitals now have electronic health records \n(EHRs). The U.S. healthcare IT market is expected to be worth $23 billion by 2017. \nThe combination of new technologies, inefficient markets, and other market dynamics — such as an \nadditional 25 million people entering the U.S. healthcare system as a result of the Affordable Care \nAct, consumerization of healthcare, prevalence of high deductible plans and promotion of \naccountable-care organizations (ACOs) — creates a unique opportunity for a new generation of \ncompanies with transformative technologies and business models to generate significant financial \nvalue. These companies have the potential to change the practice of medicine from being focused on \ntreatment to being focused on prevention and detection, as well as becoming increasingly personalized. \nThe Fund is seeking capital commitments from qualified investors. The Fund is being organized to \ncontinue the already successful investment \n... [truncated, 3067 chars — for the full page use /api/corpus/document/EFTA00617635/7 or ?id=EFTA00617635&page=7]", "char_count": 3067}, {"efta_number": "EFTA00617635", "page_number": 8, "text_content": "II. MARKET OPPORTUNITY AND ENVIRONMENT \nIn the past ten years technology and big data have profoundly affected multiple industries, such as \nretail, finance, communication, and entertainment. The impact has been especially acute in complex \nindustries with inefficiencies driven by either a historic lack of data or fragmentation of data in \nmultiple silos. The healthcare sector, however, has thus far been largely unaffected by this technology \nand big-data revolution. Recent advances in DNA sequencing, sensor and communication technology \nas well as digitization of health data have created an opportunity for technology to penetrate the \nhealthcare sector. Technology adoption in the U.S. healthcare system is further supported by dynamics \nsuch as spiraling healthcare costs, high level of inefficiencies and an improving regulatory and \nreimbursement landscape. \nInnovative technologies and tools will fundamentally change the way medicine is practiced either by \ngenerating additional data or by helping to structure and analyze existing data. The availability of data \nand tools to analyze data should lead to the practice of medicine moving from being treatment oriented \nto being prevention and detection oriented, while becoming increasingly personalized. \nTransformation of Medicine' \nNew Medicine \nC \nCd\n= \nCO \nInformation \nSystems \nWireless \nSensors \nMobile \nConnectivity \n.0,0/ \n• Bandvadth \nGenornIcs \nStipa \nInternet \nConvergence \nImaging •••••\"..... \nSocial Networking \na Computing \nPower • Data \nUniverse \nOld Medicine \nAlthough in an early stage, this transformation of healthcare is already under way. Global digital \nhealthcare data is expected to increase 50 times, from 500 petabytes in 2012 to 25,000 petabytes by \n2020.3 McKinsey & Company estimates that big-data solutions could lead to up to $450 billion in \nreduced healthcare spending in the United States. Oliver Wyman estimates that the emergence of new \npatient-centered healthcare delivery models will eliminate $5\n... [truncated, 2212 chars — for the full page use /api/corpus/document/EFTA00617635/8 or ?id=EFTA00617635&page=8]", "char_count": 2212}, {"efta_number": "EFTA00617635", "page_number": 9, "text_content": "Key Emereing Technology Trends in Healthcare \nA few key trends will enable companies to build successful businesses by leveraging technology and \nbig data in healthcare and life sciences: \n1. Costs and Speed of DNA Sequencing \nThe Human Genome Project began in 1990 and took 13 years and approximately $3 billion to map \nthe first human genome. Since then there has been significant improvement in both speed as well as \ncost of DNA sequencing. Today a human genome can be sequenced in a day for $1,000. \nThe rise of molecular medicine is a classic technology-based transformation similar to the advent of \nthe digital information era. Advances in semiconductor technology drove down the cost of computing, \nwhich allowed a growing number of users to apply powerful computing technology to routine \nactivities. This growing user base attracted innovators to create additional applications and uses, which \nfurther expanded the applicable user population, creating a virtuous cycle. In the case of DNA \nsequencing, technology improvements are occurring at an even faster rate. \nFast and affordable DNA sequencing will lead to fundamental changes in disease diagnosis and \ntreatment. DNA sequencing will allow better diagnosis of underlying molecular causes of diseases \nand also over time lead to personalized treatment. \nDNA Sequencing Cost per Human Genome (30x coverage \nCost pct G0/101114` \n5100M \n510M \nSIM \n5100K \n510K \nsIKT —I— —I— T \n—I— —I— —I— T \n—I— —I— —I— —I— —I-\n2001 2002 2003 2004 \n2005 2006 2007 \n2006 \n2009 \n2010 2011 \n2012 2013 \nIllumina estimates a $20 billion addressable market for sequencing technology and applications. \nMcKinsey & Company estimates that genomics will have a positive economic impact of up to $1.6 \ntrillion on global GDP by 2025. \n4 Source: National Institute of Health \nSTRICTLY CONFIDENTIAL \n5 \nDRAFT - Jeffery Epstein \nEFTA00617644\n", "char_count": 1876}, {"efta_number": "EFTA00617635", "page_number": 10, "text_content": "Economic Impact of Genomics in 2025 ($ \n1.2 \n0.2 \n0.2 \n9 \nHealthcare \nSubstance \nAgriculture \nproduction \n1.6 \nOthers \nTotal \nMolecular Diagnostics \nScientists have already discovered molecular causes/links to a number of diseases over the past 20 \nyears. The Online Mendelian Inheritance in Man (OMIM) database contains more than 5,000 \nconditions with known associations to genomic factors. \nSimilarly, the Catalogue of Somatic \nMutations in Cancer (COSMIC) database has information on 1.6 million mutations in 522 genes that \nare associated with various forms of cancer. \nAs researchers continue to find the molecular basis for various rare and common diseases, DNA \nsequencing is expected to enable a new disease taxonomy whereby diseases are characterized based \non cell biology rather than the traditional system of diagnosis via symptoms or point of origin. \nMolecular profiling based on this taxonomy will allow for highly precise and accurate diagnostics. \nMolecular diagnostics has seen initial success in the fields of cancer as well as pre-natal diagnostics, \nand was already a $511 million market in 2013. The sequencing-based molecular-diagnostics market \nis expected to grow at a compound annual growth rate of 72 percent to reach $7.6 billion in 2018. \nClinical Next-Generation Sequencing Market ($ million)6\n5 McKinsey & Company: Disruptive technologies \n6 Source: BCC research, July 2013 \nSTRICTLY CONFIDENTIAL \n6 \nDRAFT - Jeffery Epstein \nEFTA00617645\n", "char_count": 1471}, {"efta_number": "EFTA00617635", "page_number": 11, "text_content": "Molecular profiling will also enable better prognosis and risk predictions with the highest impact in \ncancer, a disease that is driven entirely by complex DNA changes. \nNext Generation Drug Development and Personalized Medicine \nAs research leads to the creation of large data sets linking molecular profiles to diseases, drug \ndiscovery and development is expected to also undergo a dramatic change. Better understanding of \ndiseases and their progressions, based on molecular information, should lead to many more drug \ntargets. These drugs may have smaller addressable markets, given that they will be targeted at patients \nwith particular molecular profiles. However, molecular profiling should also make it easier to select \npatients for clinical trials and to prove the efficacy of drugs in the target market at lower cost. \nAs a result, drug discovery and development will change from an expensive process relying on \nblockbuster drugs to a more efficient process, with lower development costs, focused on smaller \npatient populations where the drugs will be more effective. Together, these changes have the potential \nto reduce drug-development capital requirements and allow start-up companies to engage in drug \ndiscovery. \nAlthough personalized medicine is in the early stages of development, impressive initial successes \nhave been reported, particularly in the field of cancer. More than 800 targeted therapies are either \navailable or in the pipeline to target specific cancers.' \n2. Smart Sensors and Remote-Monitoring Devices \nSmart sensors and remote-monitoring devices allow the collection of data for applications such as \nhealth management, as well as better healthcare delivery. These devices now enable the monitoring \nof numerous health parameters in ways that were not possible before. Not only is it possible to monitor \nvarious health parameters much faster and cheaper, it can be done more frequently, which can provide \nmore accurate and reliable insight. \nWe see the fir\n... [truncated, 2965 chars — for the full page use /api/corpus/document/EFTA00617635/11 or ?id=EFTA00617635&page=11]", "char_count": 2965}, {"efta_number": "EFTA00617635", "page_number": 12, "text_content": "the United States owned a smartphone as of November 2013.8 This new tool has led to a rapid \nincrease in people who monitor their health and access health-related information. \n• \nTechnology advancements. Sensors are becoming smaller, affordable, and more accessible. \nMaterial science has advanced to create wearable sensors that can take measurements \npassively. Wireless communication allows data to be transmitted securely and accessed \nglobally. Data storage is cheap and secure. Increased computing power with cloud computing \nenables data analysis where previously impossible, providing medical practitioners and \nconsumers with more accurate and reliable insight. \n• \nChronic diseases. An aging population in the United States has led to more than 130 million \npatients suffering from chronic diseases such as diabetes, congestive heart failure, and \nhypertension. Treatment for such chronic diseases accounts for more than 75 percent of health-\nsystem costs. Remote-monitoring systems can be highly useful to manage patients who suffer \nfrom such chronic diseases'. \nHealth and Fitness Oriented Wearable Devices Shipped (millions)1°\nThe market is not limited to wearable devices alone. Increasing penetration and the computation \ncapabilities of smartphones have led to rapid development in the number of health-and-fitness-oriented \napplications and devices that reside within or connect to smartphones. \n8 Source: Comscore \n9 Source: CDC \nI° Source: BCC research, February 2014 \nSTRICTLY CONFIDENTIAL \n8 \nDRAFT - Jeffery Epstein \nEFTA00617647\n", "char_count": 1554}, {"efta_number": "EFTA00617635", "page_number": 13, "text_content": "Global Mobile Health Market (Devices. Applications. Services, and Therapeutics: $ \n3. Digital Health Platforms \nThe past three to four years have seen a rapid increase in IT penetration in doctors' offices and \nhospitals. The progress has been most significant in the field of electronic health records (EHRs), \nwith more than 50 percent of doctors' offices and 80 percent of hospitals now having EHRs.12\nPhysicians/other providers with basic EFIR\" \nEligible hospitals with basic EHR\" \nl://\ns ti en\n.,://\n44.41\n0 .44.\n0 0.044,\n4,7/4\", \nGovernment policy and reform has been one of the key drivers behind this adoption. Some of the \npolicies adopted in the Health Information Technology for Economic and Clinical Health (HITECH) \nAct of 2009 have played an important role in the creation of a digital-health ecosystem by accelerating \nthe development of necessary healthcare IT infrastructure: \n• \nMore than $17 billion of incentives for hospitals and providers to use electronic health \nrecords. \n• \nAnother $2 billion to support healthcare IT infrastructure as well as other training and \nresearch. \n\" Source: Allied market research Nov-2013 \n12 Source: htlp://www.hhs.govinews/press/2013pres/05/20130522a.Mml \nSTRICTLY CONFIDENTIAL \n9 \nDRAFT - Jeffery Epstein \nEFTA00617648\n", "char_count": 1276}, {"efta_number": "EFTA00617635", "page_number": 14, "text_content": "This continued digitization of medical and other health data has led to an opportunity for companies \nto use this data for various applications: \n• \nProviding real-time data access to doctors as well as patients. \n• \nAssisting patients in managing their health. \n• \nConnecting doctors and patients. \n• \nMonitoring things like epidemics and adverse events. \n• \nImproving clinical trials. \n• \nStreamlining processes and reducing administrative costs. \nHealthcare IT is expected to be a $23 billion market in the United States by 2017.13\nTrends Supporting Adoption of Technology in Healthcare \nAdditional market dynamics have created an environment that is expected to support the adoption of \ninnovative solutions in the U.S. healthcare market: \n1. Large and Unsustainable Healthcare Spending in the United States \nAccording to the World Health Organization, about $7 trillion was spent on global healthcare in 2011. \nAt more than 10 percent, this represents one of the largest sectors of global GDP.\" \nAt $2.8 trillion in 2012, healthcare spending in the United States is the highest of any country globally \nand represents 17.2 percent of U.S. GDP.\" Moreover, healthcare expenditures have been growing \nconsistently and grew faster than GDP in 44 of the 52 years since 1960. During this period, healthcare \nexpenditures grew cumulatively by 103 times compared with GDP growth of 30 times. \n13 Source: Research and Markets' North American Healthcare IT Market Report 2013.2017 \n14 Source: World Health Organization Global Health Expenditure Database \nIs Source: CMS NHE data for 2012 \nSTRICTLY CONFIDENTIAL \n10 \nDRAFT - Jeffery Epstein \nEFTA00617649\n", "char_count": 1649}, {"efta_number": "EFTA00617635", "page_number": 15, "text_content": "US Healthcare Spending ($ billion) and Share of GDP (%)16\n5.0 \n27 \n7.0 \n75 \n8.9 \n256 \n12.1 \n724 \n—NHE ($ bn) \n14.1 \n13.4 \n1,377 \n1,493 \n—NHE / GDP (%) \n14.9 \n15.4 \n15.5 \n1,906 \n1,778 \n1,638 \n15.5 \n2,599 \n17.4 \n2,693 \n2,793 \n17.3 \n17.2 \n1960 \n1970 \n1980 \n1990 \n2000 \n2001 \n2002 \n2003 \n2004 \n2005 \n2010 \n2011 \n2012 \nDespite a modest decline in the growth rate in recent years, healthcare continues to account for a very \nhigh portion of U.S. GDP. The Centers for Medicare and Medicaid (CMS) estimates healthcare \nspending in the United States will reach $5 trillion in 2022 and represent about 20 percent of GDP. \nLong term CMS expects healthcare costs could reach 35-40 percent of GDP. \nU.S. Healthcare Spending as % of GDP\" \n40% \n35% \n?ME Napa MO \nS0% \n25% \nNUE 0444ban a) \n20% \nNNE - limit \n15% \n10% \n0% \n- \nnm 1510 1990 MOD m10 mm m30 2040 2050 2060 2070 2040 \nC44444t \nThe high level of healthcare spending and its seemingly relentless growth are problematic for the \nUnited States. \nPublic spending on healthcare—primarily through the Medicare and Medicaid \n16 Source: CMS NHE data for 2012 \n17 Source: CMS — June 2013 \nSTRICTLY CONFIDENTIAL \n11 \nDRAFT - Jeffery Epstein \nEFTA00617650\n", "char_count": 1189}, {"efta_number": "EFTA00617635", "page_number": 16, "text_content": "programs-is crowding out other state and national priorities, including education, social security, \nnational defense, and deficit reduction. High healthcare costs for private employers inhibit the hiring \nof workers and add upward pressure on the prices of goods and services. Similar problems associated \nwith rising healthcare costs may also be observed in other developed countries. \n2. Inefficiencies in U.S. Healthcare \nThe United States spends more money on healthcare than any other nation, whether measured in terms \nof per-capita spending or spending as a percentage of GDP. McKinsey & Company estimates that the \nU.S. expenditure on healthcare is $600 billion (or 3.7 percent of GDP) more than the expected \nbenchmark for a nation of its size and wealth. \nHealthcare Expenditure / GDP To\": \nOECD Average \nUSA \n9.3 \n17.2 \nUK \n9.4 \nSweden \n9.5 \nSpain \n9.3 \nPortugal \n10.2 \nNorway \n9.3 \nNetherlands \n11.9 \nJapan \n9.6 \nItaly \n9.2 \nGermany \n11.3 \nFrance \n11.6 \nFinland \n9.0 \nCanada \n11.2 \nBelgium \n10.5 \nAustralia \n8.9 \nHealthcare expenditure per capita ($ ppp)I8: \nOECD Average \nUSA \nUK \nSweden \nSpain \nPortugal \nNorway \nNetherlands \nJapan \nItaly \nGermany \nFrance \nFinland \nCanada \nBelgium \nAustralia \nHowever, high healthcare spending has not ranslated into better outcomes, with Americans having a \nlower life expectancy than the OECD average. \n18 Source: CMS 2012 data for US, OECD 2011 data for rest \nSTRICTLY CONFIDENTIAL \n12 \nDRAFT - Jeffery Epstein \nEFTA00617651\n", "char_count": 1477}, {"efta_number": "EFTA00617635", "page_number": 17, "text_content": "Healthcare Spending Per Capita vs. Life Expectancy at Birth19\nMOOD \nOECD AVERAGE \n19.000 \nUn4ed States • \n$8.030 \n17.000 \nI \n56.000 \nI\nk scoot) \nIf \nS.3COD \n6 52033 \n/ \n51.030 \n0 \n73 \nSvntradara \n• \nNorway \nDennis' \nCanada • \nFrame \nUnited Ir4ngdom \n• \nt \n• \n9, \nn 0\nNew Zealand \n;.:. \n4.14° 494131\nPciand \n• \n• \n•\n441 \nKorea \nI•\ng \n444,440 • • \n%hey \n74 \n75 \n76 \n77 \n78 \n79 \n80 \n81 \n82 \n83 \nAverage life expectancy at birth \n3. Regulatory and Reimbursement Progress \nRegulation and reimbursement will continue to be important drivers in the success of healthcare \ncompanies. In the past few years, the Food and Drug Administration (FDA) and insurance companies \nhave supported technology-based innovation in the healthcare space. \nOn the regulatory front, the FDA has shown its support for technology-based innovation through \nvarious actions: \n• \nGranting de-novo 510(k) approval20 to Illumina's Miseq next-generation sequencing \nplatform. \n• \nGranting 510(k) approval to the iPhone-based ECG-monitoring devices \n• \nLaying out clear guidelines for the categories of mobile applications that it would seek \nto regulate (the FDA has already approved more than 100 health applications).21\n• \nHaving extensive dialog with industry on the regulation of molecular tests while \nallowing them to operate as Laboratory Developed Tests (LDTs). \n• \nStarting an expedited Program for Serious Conditions (17 breakthrough therapy \ndesignations have been granted already). \n19 OECD 2011 data \n20 510(k) approval is the FDA section that allows for the approval of Class II medical devices. Class II devices are \nmedical devices that require approval but unlike Class III devices are not required to sustain life or implanted within the \nhuman body. \n21 Source: \nSTRICTLY CONFIDENTIAL \n13 \nDRAFT - Jeffery Epstein \nEFTA00617652\n", "char_count": 1813}, {"efta_number": "EFTA00617635", "page_number": 18, "text_content": "In addition, other governmental agencies are also increasingly working with the FDA. The National \nInstitutes of Health (NIH) created the Accelerating Medicines Partnership (AMP) as a new model for \nspurring development of drugs toward FDA approval. \nOn the reimbursement front, several factors favor companies providing innovative healthcare \nsolutions: \n• \nConsumerization of healthcare means that patients play an increasingly important role \nin their treatment. Patients pay $328 billion (11.7 percent) of healthcare expenditures \nout-of-pocket. Private health insurance provided an additional $917 billion: initiatives \nsuch as high-deductible health plans are increasingly shifting the burden of healthcare \ncosts onto consumers. \n• \nNew models such as ACOs reward providers for positive patient outcomes and give \nproviders incentives to use the most cost-effective solutions. \n• \nValue-based payments for specific health outcomes are helping to align incentives \namong providers, consumers, and health plans. Some outcomes, such as prevention of \nhospital re-admissions and shortening of sick time, demonstrate cost effectiveness and \nthe justification to invest in the future of sensor-based technologies. \nSTRICTLY CONFIDENTIAL \n14 \nDRAFT - Jeffery Epstein \nEFTA00617653\n", "char_count": 1281}, {"efta_number": "EFTA00617635", "page_number": 19, "text_content": "III. INVESTMENT STRATEGY \nPhilosophy \nThe Fund has invested and intends to continue investing in companies at the intersection of technology, \nmedicine, and life sciences. Technology and big data will play a major role in resolving inefficiencies \nin the health care system. \nRecent advances in DNA sequencing, sensor and communication \ntechnology, and the digitization of health data create an opportunity to dramatically reduce \ninefficiencies in diagnosis, treatment, and the delivery of health care. These advances will provide \nopportunities for companies with transformative technologies and business models to create \nsignificant financial value. \nThe Fund aims to achieve superior, risk-adjusted returns by targeting and investing in companies with \nproven technology and low regulatory and reimbursement risks. Typical investments are expected to \nbe approximately $10 million in primary, secondary and tertiary offering rounds of companies based \nprimarily in the United States. The Fund intends that its exits will take the form of initial public \nofferings or mergers and acquisitions and will be timed to maximize investor returns with expected \nholding periods of five (5) to seven (7) years. \nInvestment Criteria \nThe Fund will typically look for the following key characteristics in target companies while \nconsidering an investment: \n1. Strong Chief Executive Officer and Team \nThe primary and most important asset of a company is its people. In particular, strong and capable \nleadership is essential not only for retaining and motivating key employees but also for turning good \nideas and products into profitable enterprises. The Fund places considerable emphasis on the chief \nexecutive officer (CEO) and the senior management team with a focused analysis of their ability to \nmanage people, background, integrity, underlying motivations, and overall ambitions and vision. \n2. Significant and Proven Technology Advantage within Well-defined Strategic Areas \nThe Fund seeks to inv\n... [truncated, 2902 chars — for the full page use /api/corpus/document/EFTA00617635/19 or ?id=EFTA00617635&page=19]", "char_count": 2902}, {"efta_number": "EFTA00617635", "page_number": 20, "text_content": "4. Large Addressable Market \nBiosys has sought and will continue to seek target companies focused on large markets in terms of the \nnumber of people who can be impacted by the technology, whether through physicians or directly to \nconsumers. The Fund has sought and will continue to seek target companies that are preparing to \nlaunch already successful products or services to the global healthcare market. \nSTRICTLY CONFIDENTIAL \n16 \nDRAFT - Jeffery Epstein \nEFTA00617655\n", "char_count": 474}, {"efta_number": "EFTA00617635", "page_number": 21, "text_content": "IV. INVESTMENT PROCESS \nDeal Sourcing \nDeal sourcing is a strategic focus for the Fund, which includes identifying the right companies and \ncreating the opportunity to invest in them. The Fund's access to the highest quality and well-\ndifferentiated deal flow is one of its key strengths. \nThe Principals have received and expect to continue to receive referrals from several unique sources \nincluding: founders of technology and healthcare companies that the Principals have previously \ninvested in or know; investment funds that value the Principals' technical and strategic knowledge; \nand entities associated with one of Biosys's anticipated first investors, Bill Gates. \nThe Principals have longstanding relationships with leading entrepreneurs, inventors, scientists, \nacademicians, pharmaceutical and biotech company executives and physicians. Additionally, they \nhave strong relationships with public and global health organizations, foundations, national scientific \nbodies and organizations, insurers and other corporate payers. These networks provide Biosys access \nto the highest quality entrepreneurs and companies. The Principals' past experience of co-investing \nand relationship building with top-tier venture investors allows the Fund to gain exposure to promising \ncompanies in their portfolios. \nThe Principals' relationship network and sources of referrals not only provide access to companies, \nbut also add unique insights for the evaluation of potential investments. \nBiosys has researched and will continue to research target industry sectors extensively, while closely \ntracking private companies that fit the Fund's investment criteria. The Principals will maintain very \nclose relationships with key decision makers of the companies that are tracked. \nThe international network of the Principals brings together valuable flows of information, perspective \non opportunities and resources that are highly beneficial to portfolio companies. As a result, Biosys \nexpects to rec\n... [truncated, 3086 chars — for the full page use /api/corpus/document/EFTA00617635/21 or ?id=EFTA00617635&page=21]", "char_count": 3086}, {"efta_number": "EFTA00617635", "page_number": 22, "text_content": "2) Underlying science and technology. Considerable time will be spent understanding the \nunderlying science of the company and the resulting technical advantage. The Principals will \nutilize their extensive network of science and domain experts to better understand the \ntechnology advantage and risks. \n3) Market potential, business model, and competition. Biosys will extensively research the size \nand growth prospects of a company's target market and conduct interviews with existing or \npotential customers to understand their perspective. Given the Principals' extensive network, \nthey should be able to speak to most of the players in a particular space to evaluate threats from \nexisting or new competitors before deciding upon an investment \n4) Intellectual property (IP). Biosys will engage experienced attorneys in specific fields to \nvalidate freedom-to-operate and exclusivity position and to identify blocking IP. \nPortfolio Management \nThe Fund will actively engage in frequent dialog with the key management team of its portfolio \ncompanies. Historically, the Principals have dedicated, and expect to continue dedicating, significant \ntime to develop deep relationships with key decision makers in the Fund's portfolio companies. \nWe expect that the Fund's Portfolio companies will appreciate the Principals' previous experience in \ninvesting and monitoring the industry, as well as their strong connections globally. Where appropriate, \nthe Principals will provide advice and introductions to the Fund's portfolio companies. \nThe Principals will typically take a board-observer seat and/or ask for regular updates on business \nprogress from the Fund's portfolio companies. Board participation, regular updates, and active \nmonitoring of other available information regarding portfolio companies and their competitors will \nallow Biosys to remain up-to-date on the growth and competitive environment of the Fund's \ninvestments. \nThe Fund will seek to increase its stake in a portfolio\n... [truncated, 2498 chars — for the full page use /api/corpus/document/EFTA00617635/22 or ?id=EFTA00617635&page=22]", "char_count": 2498}, {"efta_number": "EFTA00617635", "page_number": 23, "text_content": "V. INVESTMENT COMMITTEE \nThe investment team will initially be composed of Boris Nikolic, Hayes Nuss, Peter Corsell and David \nSchwarz (the \"Investment Committee\"). We expect that Boris will lead the sourcing, diligence, \nevaluation and monitoring of portfolio investments. We expect that Hayes will support with \ninvestment analysis and due diligence as well as manage the fund accounting, finance, compliance \nand all administrative and operational infrastructure. We expect that Peter and David will support \nBiosys with sourcing, strategic advice, due diligence and negotiations. The Fund may add new \ninvestment professionals as needed, from time to time. \nBoris Nikolic \nBoris Nikolic is a Managing Director of the General Partner of Biosys. Most recently, Dr. Boris \nNikolic served as Chief Advisor for Science and Technology to Bill Gates at bgC3, the private office \nof Bill Gates, and at the Bill & Melinda Gates Foundation (BMGF). Dr. Nikolic joined the BMGF in \nOctober 2007 and bgC3 in April 2010. \nDr. Nikolic has led select for-profit and not-for-profit investment activities at the aforementioned \nGates-affiliated organizations. On the for-profit side, Dr. Nikolic has led investments in various life-\nscience/IT/healthcare companies such as Foundation Medicine and Research Gate, served on the board \nof directors of Schrodinger, and monitored Nimbus. On the not-for-profit side, Dr. Nikolic co-\nmanaged BMGF's $1.5 billion strategic-investment pool, focused on program-related investments in \nhealth. Dr. Nikolic focused on biotechnology investments specifically and pioneered direct-equity \ninvestments of BMGF in companies with platform technologies such as Liquidia, Genocea, Visterra, \nAtreca, and Anacor. At BMGF, Dr. Nikolic also led the discovery program of the novel mHealth, \ndiagnostics platform technologies, molecular diagnostics point-of-care applications, and vaccination \nand surveillance technologies. \nDr. Nikolic received his MD from Zagreb Medical School and his\n... [truncated, 3512 chars — for the full page use /api/corpus/document/EFTA00617635/23 or ?id=EFTA00617635&page=23]", "char_count": 3512}, {"efta_number": "EFTA00617635", "page_number": 24, "text_content": "diagnostics with therapeutics, and Aquatrove, Inc., which is focused on developing unique conception-\npromoting and infertility diagnostics products. \nHayes Nuss \nHayes Nuss, a Managing Director of the General Partner of Biosys, was formerly Managing Director \nfor Risk Management and Analytics and a Principal at Strategic Investment Group, an investment \nmanagement firm with $32 billion in client assets. Nuss rose from analyst to Principal in eight years \nbased on his talent for finance, management, and business operations forensics, which he used in due \ndiligence of potential investments, for tailoring portfolio strategies to the needs of clients and in \noverseeing the redevelopment of the firm's investment infrastructure. \nNuss' ability to analyze and optimize business operations was a hallmark of his career at Strategic, \nwhere he employed innovative methods to research and perform due diligence on potential \ninvestments for client portfolios. His training as an aerospace engineer, his problem-solving and \nforensic experience for the US Navy, in addition to his MBA and financial experience, equipped him \nwith a broad range of processes and perspectives for evaluating business effectiveness and growth \npotential. \nAs a member of the investment committee at Strategic Investment Group, Nuss was responsible for \ndeveloping client-specific investment policies, risk management, investment analytics and technology. \nHe applied the same analytic eye to his corporate clients to help shape their retained earnings \nstrategies. With clients such as the Cleveland Clinic and Dignity Health, Nuss dug deep into client \nbusiness practices to help them align their investment strategy with business risks and objectives. \nNuss also managed most aspects of Strategic's investment infrastructure and developed new processes \nand systems that enhanced operations from the front to back office of the firm. Additionally, he \ndeveloped innovative and industry-leading investment management a\n... [truncated, 3080 chars — for the full page use /api/corpus/document/EFTA00617635/24 or ?id=EFTA00617635&page=24]", "char_count": 3080}, {"efta_number": "EFTA00617635", "page_number": 25, "text_content": "development and capital formation process to commercial viability. He developed GridPoint, a \nprovider of energy management technology, from initial prototype in 2004 into an established \ncleantech leader and a pioneer in the Internet of Things. More recently, he has built and capitalized \nHubub, inStream and Clearpath — all companies developed around signature digital products. \nCorsell has managed multiple equity and debt financings for technology companies and has raised \nover $300 million in operating capital for his businesses. He has fostered a diversified stable of \ninvestors, ranging from major institutions to high net worth individuals to corporations. Most recently, \nhe secured a major investment from Canada's largest communications company. \nCorsell is known for building creative relationships that unlock new value for stakeholders. He has \nclose marketing partnerships with Goldman Sachs, Bell Canada, Univision and others, and he has \ndeveloped first-of-their-kind digital tools that turn customers into sales and marketing partners. In the \nprocess of building companies around new hardware and software products, Corsell has built expertise \nin the patent application and intellectual property protection process. He has also attracted and led \nsenior executives from top companies including Berkshire Hathaway, Microsoft, Siemens, Accenture, \nYahoo!, Bell Canada, Ciena, Neustar and Xcel Energy. \nCorsell brings the perspective of a successful practitioner to the Investment Committee, helping to \nevaluate prospective portfolio companies, structure equity investments, and assess operational \neffectiveness. He also serves as a resource to the Fund's partner entrepreneurs, drawing on his \nexperience and expertise to address the challenges and opportunities faced by growth stage companies. \nEarlier in his career, Corsell served with the U.S. Department of State in Havana, Cuba, and as a \npolitical analyst at the Central Intelligence Agency. He holds a BSFS degree fr\n... [truncated, 3415 chars — for the full page use /api/corpus/document/EFTA00617635/25 or ?id=EFTA00617635&page=25]", "char_count": 3415}, {"efta_number": "EFTA00617635", "page_number": 26, "text_content": "Schwarz is also an active investor in venture-stage private companies in a wide variety of sectors, \nincluding technology, entertainment, and real estate. Schwarz is a highly-engaged and experienced \ninvestor, diagnosing and testing companies' financial structures, business models and business \nstrategy. \nSchwarz received his bachelor's degree at St. John's College in Annapolis, MD and earned his \nmaster's degree at Yale University. Schwarz's featured work includes The Nancy Lee and Perry R. \nBass Performance Hall, Cook Children's Medical Center, Yale Environmental Science Center, and \nthe Schermerhorn Symphony Center. He is Chairman of Yale School of Architecture's Dean Council. \nHe is the Chairman of the Vincent J. Scully Prize Fund Endowment for the National Building Museum, \nwhich is among the most prestigious awards in urban design. \nSTRICTLY CONFIDENTIAL \n22 \nDRAFT - Jeffery Epstein \nEFTA00617661\n", "char_count": 916}, {"efta_number": "EFTA00617635", "page_number": 27, "text_content": "VI. SUMMARY OF PRINCIPAL TERMS OF THE FUND \nThe Fund \nBiosys Capital Partners, LP, a Delaware limited partnership (\"Biosys\" \nor the \"Fund\"). \nInvestment Objective To make non-controlling investments in private companies in the \nhealthcare and life-sciences industry with a valuation of less than $750 \nmillion. \nThe Fund expects to primarily invest in companies \nheadquartered in North America. \nGeneral Partner \nBiosys Capital Management, LLC, a Delaware limited liability company \n(the \"General Partner\"). \nMinimum Capital \nCommitment: \nGeneral Partner's \nCapital Commitment \n$10 million, provided that the General Partner reserves the right to waive \nthis minimum from qualified investors (\"Limited Partners\" and \ncollectively with General Partner the \"Partners\"). \nThe General Partner, its members and/or their affiliates will commit to \ninvest in the Fund a sum equal to the lesser of (i) $15 million and (ii) ten \npercent (10%) of the aggregate capital commitments made by Limited \nPartners (other than members of the General Partner and/or their \naffiliates) to the Fund (the capital commitments of the Partners being \nreferred to as the \"Capital Commitments\"). The General Partner may \ntransfer such capital between and among the Fund, any Alternative \nInvestment Vehicle (as defined below), and any Parallel Fund (as \ndefined below). \nInvestor Suitability \nEach Limited Partner must be a \"qualified purchase?' as defined in the \nInvestment Company Act of 1940, as amended, and must meet certain \nother financial and suitability criteria established by the General Partner. \nThe relevant qualifications will be set forth in subscription documents \nsubsequently distributed to potential investors by the Fund, which \ndocuments must be completed by each prospective investor. The \nGeneral Partner reserves the right to reject any subscription in its sole \ndiscretion. \nTerm \nInvestment Period \nThe Fund's term will terminate on the tenth anniversary of the Initial \nClosing (as defined below); \n... [truncated, 2439 chars — for the full page use /api/corpus/document/EFTA00617635/27 or ?id=EFTA00617635&page=27]", "char_count": 2439}, {"efta_number": "EFTA00617635", "page_number": 28, "text_content": "Date (unless such period is extended under very limited circumstances \ndescribed in the Partnership Agreement); provided, however, that, after \nthe end of such period (the \"Investment Period\") the Partners will have \na continuing obligation to make contributions to finance portfolio \ninvestments which were in process as of the end of the Investment \nPeriod, to finance follow-on investments, to pay Fund expenses and as \notherwise set forth in the Partnership Agreement; provided that capital \ncontributions called by the General Partner with respect to follow-on \ninvestments after the end of the Investment Period will not exceed the \nlesser of (i) 20% of the aggregate Capital Commitments of the Partners \nto the Fund, and (ii) the aggregate unfunded Capital Commitments of \nthe Partners to the Fund as of such time. \nBridge Financings \nAdvisor \nThe Fund may provide interim financing or guarantees to one or more \ntarget companies (\"Bridge Financing\") in order to facilitate the Fund's \ninvestment in such companies. All Bridge Financings will be (i) senior \nto the permanent investment of the Fund in the target company, (ii) bear \ninterest or carry other compensation at amounts determined to be \nappropriate by the General Partner, and (iii) have a final maturity of not \nmore than one year. Any Bridge Financing which has not been repaid, \nsold to or refinanced by a third party within one year will be treated in \nthe same manner as the Fund's other investments for all purposes. \nThe Advisor will provide advisory services to the Fund, including \ninvestigating, structuring and negotiating potential Investments, \nmonitoring investments post-acquisition, and advising the Fund with \nrespect to disposition opportunities. The advisory services will be \nprovided under the terms and conditions of an Advisory Agreement \nentered into by and among the Partnership and the Advisor. \nInvestment \nThe General Partner will select a four-member investment committee \nCommittee \nwhich will meet (i)\n... [truncated, 3019 chars — for the full page use /api/corpus/document/EFTA00617635/28 or ?id=EFTA00617635&page=28]", "char_count": 3019}, {"efta_number": "EFTA00617635", "page_number": 29, "text_content": "opportunities (as described below). Until the Fund makes its first \ninvestment, the Management Fee will be paid directly by the Limited \nPartners to the Advisor (which payments will reduce their unfunded \nCapital Commitments). \nCarried Interest Rate 20%, as described in greater detail under the heading \"Distribution \nPriorities\" below. \nTiming of \nThe General Partner intends that investment proceeds generally, net of \nDistributions \nany provision for income taxes and expenses (including tax distributions \nto the General Partner), will be distributed as soon as practicable after \nreceipt thereof. The General Partner intends that current cash receipts \n(\"Current Income\") from dividends, interest and other non-tax \ndistributions from the Fund's investments net of income taxes and \nexpenses (including tax distributions to the General Partner) will be \ndistributed at least annually. \nDistribution \nEach distribution of investment proceeds from the sale of all or a portion \nPriorities \nof a Fund investment or the receipt of current cash from dividends, \ninterest and other non-sale cash distributions from a Fund investment \nshall be apportioned among the Partners as follows. The amount \napportioned to the General Partner (and its affiliates, including any \nLimited Partners that are affiliates of the General Partner) shall be \ndistributed to the General Partner (and such affiliates), and the other \nPartners' apportioned share of any distribution shall be distributed as \nfollows: \n1. Return of Capital Contributions: First, 100% to the Partners until \neach Partner has received cumulative distributions from the Fund \nequal to the aggregate capital contributions to the Fund made by \nsuch Partner; and \n2. 80/20 Split: Thereafter, 80% to the Partners and 20% to the \nGeneral Partner. \nIf distributions in accordance with the above distribution priorities in \nany given year would not result in the General Partner receiving amounts \nat least equal to the income taxes imposed on it or \n... [truncated, 2761 chars — for the full page use /api/corpus/document/EFTA00617635/29 or ?id=EFTA00617635&page=29]", "char_count": 2761}, {"efta_number": "EFTA00617635", "page_number": 30, "text_content": "\"Distribution Priorities\"), the General Partner will refund such excess \ndistributions provided that the General Partner shall not be required to \nrefund an amount in excess of the cumulative distributions (exclusive of \nthe General Partner's distributions in respect of the General Partner's \ncommitted capital) received by the General Partner less taxes paid or \ndeemed paid by the General Partner in respect of its carried interest. The \nobligations of the General Partner under this General Partner's \nClawback will be severally guaranteed by the members of the General \nPartner. \nPartner Giveback \nObligation \nAllocation of Profit \nand Loss \nCapital Calls \nExcuse, Exclusion \nand Withdrawal \nIn addition to any requirements of applicable law, until the third \nanniversary of a distribution (or thereafter with regard to a proceeding \npending on such date) the General Partner may require a Partner to return \ndistributions made to such Partner for the purpose of meeting the \nPartner's pro rata share of partnership liabilities and obligations, \nincluding any indemnity obligations, as further described in the \nPartnership Agreement; provided, however, that the aggregate amount \nof distributions which a Partner may be required to return shall not \nexceed an amount equal to 30% of such Partner's Capital Commitment. \nThe Fund will establish and maintain a capital account for each Partner. \nAll items of income, gain, loss, and deduction will be allocated to the \nPartners' capital accounts in a manner generally consistent with the \ndistribution provisions outlined above. \nIn general, the Partners will make capital contributions in respect of their \nCapital Commitments on an \"as needed\" basis, on ten (10) calendar \ndays' notice. \nA Limited Partner may be excused from funding an investment if its \nparticipation would otherwise violate a law or regulation to which it is \nsubject. The General Partner may exclude a Limited Partner from \nparticipating in an investment if the General Part\n... [truncated, 2892 chars — for the full page use /api/corpus/document/EFTA00617635/30 or ?id=EFTA00617635&page=30]", "char_count": 2892}, {"efta_number": "EFTA00617635", "page_number": 31, "text_content": "regulations under ERISA; (ii) the Fund or any Partner may be subject to \nany requirement to register under the Investment Company Act of 1940, \nas amended; or (iii) a significant delay, extraordinary expense or \nmaterial adverse effect on the Fund or any of its affiliate, any portfolio \ncompany, or any prospective investment is likely to result. \nInitial and \nAn initial closing of the Fund (the \"Initial Closing\") will be held once \nSubsequent Closings \nthe General Partner determines that a sufficient minimum amount of \ncommitments has been obtained. Subsequent closings may occur at the \ndiscretion of the General Partner; provided that such closings shall occur \nno later than eighteen months following the date of the Initial Closing \n(the \"Final Closing Date\"). \nLimited Partners admitted (and existing Limited Partners increasing \ntheir Capital Commitments) subsequent to the Initial Closing will pay \ntheir pro rata share of all funded Capital Commitments which have been \napplied to any investments then held by the Fund, Management Fees, \nand certain expenses, plus interest thereon at an annual rate equal to 1-\nmonth LIBOR + 6% (such interest being referred to herein as the \n\"Additional Amount\"). Such amounts will be allocated and distributed \nto previously admitted Partners or the Advisor, as applicable. Amounts \nso distributed to previously admitted Partners (other than any portion of \nthe Additional Amount) will be restored to such Partners' unfunded \nCapital Commitments and be subject to recall during the Investment \nPeriod. \nIf the General Partner, in its discretion, determines that a pro rata capital \ncontribution from Limited Partners at a subsequent closing would not \nappropriately reflect a material change in the value of the investments \nthen held by the Fund (due to the occurrence of a Write-Up Event or \notherwise), the General Partner may adjust the capital contribution \nrequired to be made by Limited Partners at such subsequent closing to \nappropriately re\n... [truncated, 2942 chars — for the full page use /api/corpus/document/EFTA00617635/31 or ?id=EFTA00617635&page=31]", "char_count": 2942}, {"efta_number": "EFTA00617635", "page_number": 32, "text_content": "company) that, in the General Partner's sole discretion, establishes a \nvaluation for such portfolio company that is greater than the Acquisition \nValue of the Fund's investment in such portfolio company. For each \ninvestment in a portfolio company, the Fund's \"Acquisition Value\" shall \nmean the post-money valuation of the applicable portfolio company at \nthe time of such investment increased by an amount equal to interest \nthereon at rate equal to one month LIBOR + 6%. \nUse of Proceeds \nThe proceeds of this offering will be used to (i) pay certain costs \nassociated with the offering; (ii) pay the Management Fee (as hereinafter \ndefined), and (iii) provide the Fund with an amount of funds with which \nto identify and evaluate companies, assets or businesses with a view to \nmaking appropriate investments. After deducting expenses associated \nwith this Offering, the proceeds of this offering will only be sufficient \nto identify and evaluate a finite number of assets and businesses, and \nadditional funds may be required to finance any investment to which the \nFund may commit. \nBorrowings and \nGenerally, the General Partner on behalf of the Fund and its subsidiaries \nGuarantees \nmay borrow funds and enter into credit, financing, or refinancing \narrangements as it determines to be appropriate. In this regard, the \nGeneral Partner may cause the Fund to provide one or more guarantees \nin connection with any such debt of the Fund or its subsidiaries. \nThe General Partner may enter into one or more subscription facilities \nin order to provide the Fund with adequate working capital and satisfy \nthe short-term needs of the Fund. Any such subscription facility may be \nsecured by the unpaid Capital Commitments of the Partners (and the \nGeneral Partner may assign to the lender the right to draw upon such \nunpaid Capital Commitments of the Partners). In connection with a \nsubscription facility, each Limited Partner agrees to provide certain \ninformation, acknowledgments, and assura\n... [truncated, 2785 chars — for the full page use /api/corpus/document/EFTA00617635/32 or ?id=EFTA00617635&page=32]", "char_count": 2785}, {"efta_number": "EFTA00617635", "page_number": 33, "text_content": "disapprove certain transactions and to waive certain investment \nrestrictions, as described in the Partnership Agreement, but generally \nwill have no other power to participate in the Fund's management. The \nAdvisory Committee will not necessarily represent the interests of all \nLimited Partners, and the members of the Advisory Committee may be \nsubject to conflicts of interest. See Section VII — Certain Investment \nConsiderations and Risk Factors — Conflicts of Interest. \nDiversification Limit \nWithout the prior approval of the Advisory Committee, the Fund will \nnot make an investment in a portfolio company, if, as a result, the Fund \nwould have invested (on a net basis after taking into account any \ndistributions received by the Fund with regard to such investment that \nrepresent a return of capital) more than the greater of (i) twenty percent \n(20%) of the aggregate Capital Commitments in such portfolio company \n(or its affiliates) (including any related Bridge Financings), or (ii) $20 \nmillion in the aggregate in such portfolio company; provided that, for \npurposes of these limitations, there shall be disregarded any portion of a \nfollow-on investment by the Fund that merely represents the Fund's \"pro \nrata\" share of a financing round, with such \"pro rata\" share determined \nbased upon the Fund's percentage ownership of the portfolio company's \noutstanding equity immediately prior to such investment. \nEarly Termination \nThe Fund may be dissolved at any time upon the vote of 80%-in-interest \nof the Limited Partners (based on their respective Capital \nCommitments). \nTransfer of Interests \nA Limited Partner may not sell, assign, or transfer any interest in the \nand Withdrawal \nFund without the prior written consent of the General Partner, which \nmay be given or withheld in the General Partner's sole and absolute \ndiscretion. Further, a Limited Partner generally may not withdraw any \namount from the Fund. \nExpenses \nThe General Partner, the Advisor, and any of their \n... [truncated, 2902 chars — for the full page use /api/corpus/document/EFTA00617635/33 or ?id=EFTA00617635&page=33]", "char_count": 2902}, {"efta_number": "EFTA00617635", "page_number": 34, "text_content": "ordinary course of its activities, (v) all costs and expenses associated \nwith the purchase (or attempted purchase), holding or sale or exchange \nor other disposition of portfolio securities or other Fund assets, \nincluding, but not by way of limitation, placement and finder's fees paid \nto third-parties unaffiliated with the General Partner related to the \nacquisition or disposition of Fund assets, transfer, capital and other \ntaxes, duties and fees and travel costs associated with evaluation, \nmonitoring or disposition of portfolio securities, (vi) research expenses, \n(vii) fees and expenses of investment advisers and independent \nconsultants unaffiliated with the General Partner that are incurred in \ninvestigating and evaluating investment opportunities, acquiring and \ndisposing of Fund assets and maintaining and monitoring the Fund's \nassets, (viii) banking, brokerage, broken-deal, registration, qualification, \nfinders, depositary and similar fees or commissions, (ix) expenses \nassociated with meetings of the Limited Partners and the Advisory \nCommittee, (x) insurance premiums, indemnifications, costs of \nlitigation and other extraordinary expenses, (xi) costs of financial \nstatements and other reports to Partners as well as costs of all \ngovernmental returns, reports and other filings, (xii) interest and other \nexpenses relating to any indebtedness of the Fund, (xiii) amounts paid \nto or for the benefit of portfolio companies, (xiv) advertising and public \nnotice costs, (xv) insurance costs and expenses relating to protection \nagainst liability for loss and damage which may be occasioned by the \nactivities to be engaged in by the Fund, including, for the avoidance of \ndoubt, indemnity payments and premiums for insurance protecting the \nFund and any indemnitees from liabilities to third persons in connection \nwith the Fund's business and affairs and E&O or similar insurance \ncoverage, (xvi) the fees, costs and expenses (including due diligence \ncosts) incurred i\n... [truncated, 3187 chars — for the full page use /api/corpus/document/EFTA00617635/34 or ?id=EFTA00617635&page=34]", "char_count": 3187}, {"efta_number": "EFTA00617635", "page_number": 35, "text_content": "be lifted and the Investment Period shall be extended by the amount of \ntime during which the Investment Period was suspended. \nSuccessor Fund \nWithout the prior consent of the Advisory Committee, no Principal shall \ncommence investing on behalf of another pooled investment vehicle (or \nmanaged account) with the same investment objectives as the Fund until \nthe earlier of (a) the expiration or earlier termination of the Investment \nPeriod, (b) the date on which at least 70% of the Fund's Capital \nCommitments have been invested, expended, committed and/or reserved \nfor future investments in existing portfolio companies and for \nreasonably anticipated Fund expenses (at which time the Fund shall be \ndeemed to be \"Fully Invested\"), and (c) the dissolution of the Fund; \nprovided that this limitation shall not apply to any Parallel Funds, any \nco-investment vehicle, or any Alternative Investment Vehicle (as \ndefined below). \nParallel Funds \nAlternative \nInvestment Vehicles \nFeeder Funds \nThe General Partner may form one or more limited partnerships or other \ninvestment vehicles or investment advisory programs to invest in \nparallel with the Fund (each a \"Parallel Fund\") in order to comply with \nsecurities laws or to address tax, legal, regulatory, policy, investment \nrestriction or similar issues of investors. To the extent practicable, and \nsubject to any changes or adjustments as are necessitated by the legal, \ntax, regulatory or other considerations applicable to the Fund or to one \nor more of the Parallel Funds, each Parallel Fund shall invest in every \ninvestment made by the Fund (other than short-term investments, as \ndetermined by the General Partner) at the same time and on substantially \nthe same terms as the Fund. \nFor legal, tax, or regulatory reasons, the General Partner may determine \nthat it is in the best interests of the Partners that an investment be made \nthrough an alternative investment vehicle (an \"Alternative Investment \nVehicle\"). The General Partne\n... [truncated, 2875 chars — for the full page use /api/corpus/document/EFTA00617635/35 or ?id=EFTA00617635&page=35]", "char_count": 2875}, {"efta_number": "EFTA00617635", "page_number": 36, "text_content": "Exclusivity: \nSide Letters \nDefault \nRemoval of General \nPartner and Early \nTermination of \nInvestment Period \nfor Cause: \nparties (including persons or entities of strategic commercial \nimportance). With the prior approval of the Advisory Committee and \nsubject to the restrictions set forth in the Partnership Agreement, (i) the \nFund may co-invest in companies in which the General Partner, the \nPrincipals or any affiliates of the General Partner or the Principals have \npreviously invested; and (ii) the General Partner may offer the \nPrincipals, and/or any affiliates of the General Partner or the Principals \nthe opportunity to co-invest with the Fund. \nFrom the initial closing of the Fund until the earlier of (x) the expiration \nor earlier termination of the Investment Period, and (y) such time after \nthe Final Closing Date as the Fund is Fully Invested, each Principal shall \noffer investment opportunities that satisfy the Fund's investment criteria \nfirst to the Fund and any Parallel Funds (and among them based on their \nrelative Capital Commitments); provided, however, that (a) any \ninvestment opportunity in excess of what the General Partner determines \nis appropriate for the Fund may be offered to co-investors as further \ndescribed in the Partnership Agreement, (b) the General Partner may \nallocate an investment between the Fund and a successor fund, in equal \namounts or on such other basis as the General Partner determines to be \nreasonable under the circumstances and (c) a Principal need not offer to \nthe Fund or any Parallel Funds any investment opportunity in entities in \nwhich the Principal acquired an investment interest prior to the Initial \nClosing. \nThe General Partner, on its own behalf or on behalf of the Fund, may \nenter into letter agreements or other similar agreements (commonly \nreferred to as \"side letters\") with one or more of the Fund's investors \nwhich provide such investor(s) with additional and/or different rights \nthan other investors in th\n... [truncated, 2954 chars — for the full page use /api/corpus/document/EFTA00617635/36 or ?id=EFTA00617635&page=36]", "char_count": 2954}, {"efta_number": "EFTA00617635", "page_number": 37, "text_content": "the General Partner has committed a material violation of applicable \nsecurities laws (as established by a court or regulatory authority of \ncompetent jurisdiction in a final determination) which has a material \nadverse effect on the business of the Fund or the ability of the General \nPartner to perform its duties under the terms of the Partnership \nAgreement, or (iii) the General Partner or any Principal commits an act \nconstituting fraud, bad faith or willful misconduct in connection with the \nperformance of his/its duties under the terms of the Partnership \nAgreement as established by a court of competent jurisdiction in a final \njudgment or upon an admission by the General Partner or Principal, as \napplicable, in a settlement of any lawsuit. The General Partner generally \nhas thirty days to cure the events constituting Cause and shall be deemed \nto have cured any conduct of Principals constituting Cause if the \nemployment of the person whose conduct gave rise to such event \nconstituting Cause is terminated, and the Fund is indemnified by the \nGeneral Partner and made whole for any liabilities, losses or expenses \ncaused by such conduct. \nRemoval of General \nLimited Partners (other than any Limited Partners that are affiliates of \nPartner without \nthe General Partner) representing at least eighty percent (80%) in interest \nCause \nof the Partners (based on their respective Capital Commitments) will \nhave the right to remove the General Partner at any time without Cause. \nReports \nLimited Partners will receive semi-annual unaudited summary financial \ninformation as well as annual audited financial statements of the Fund. \nIn addition, each Limited Partner will be provided annually a pro-forma \nIRS Schedule K-1 and such other information as may reasonably be \nrequested by such Limited Partner as necessary for the completion of \nU.S. federal income tax returns. \nAmendments \nLegal Counsel \nExcept for certain limited circumstances, the Partnership Agreement \nmay only b\n... [truncated, 2485 chars — for the full page use /api/corpus/document/EFTA00617635/37 or ?id=EFTA00617635&page=37]", "char_count": 2485}, {"efta_number": "EFTA00617635", "page_number": 38, "text_content": "VII. CERTAIN INVESTMENT CONSIDERATIONS AND RISK FACTORS \nAn investment in the Fund involves a high degree of risk, and is suitable only for investors of \nsubstantial means who have no immediate need for liquidity of the amount invested and who can afford \na risk of loss of all or a substantial pan of such investment. In addition to factors set forth elsewhere \nin this Memorandum, prospective investors should carefully consider the following. \nRisks Associated with Portfolio Investments \nIdentifying and participating in attractive investment opportunities and assisting in the success of \nhealthcare and life sciences companies is difficult. There is no assurance that the Fund's investments \nwill be profitable, and there is a substantial risk that the Fund's losses and expenses will exceed its \nincome and gains. Any return on investment to the Limited Partners will depend upon successful \ninvestments made on behalf of the Fund by the General Partner. There generally will be little or no \npublicly available information regarding the status and prospects of portfolio companies. Many \ninvestment decisions by the General Partner will be dependent upon the ability of the Fund's \nInvestment Committee to obtain relevant information from non-public sources, and the General \nPartner often will be required to make decisions without complete information or in reliance upon \ninformation provided by third parties that is impossible or impracticable to verify. The marketability \nand value of each investment will depend upon many factors beyond the General Partner's control. \nTypically, the Fund will hold minority positions in portfolio companies or acquire securities that are \nsubordinated vis-à-vis other securities as to economic, management or other attributes. Specifically, \nthe Fund may invest in common or \"ordinary\" shares instead of preferred shares of a company (which \nwould be typical of other venture capital and private equity funds) and therefore the Fund may not \nhave a \"\n... [truncated, 4130 chars — for the full page use /api/corpus/document/EFTA00617635/38 or ?id=EFTA00617635&page=38]", "char_count": 4130}, {"efta_number": "EFTA00617635", "page_number": 39, "text_content": "disposing of such securities. Similarly, the receptiveness of potential acquirers to the Fund's portfolio \ncompanies will vary over time and, even if a portfolio company investment is disposed of via a merger, \nconsolidation or similar transaction, the Fund's stock, security or other interests in the surviving entity \nmay not be marketable. There can be no guarantee that any portfolio company investment will result \nin a liquidity event via public offering, merger, acquisition or otherwise, and there is a significant risk \nthat the Fund's investments will yield little or no return. Generally, the investments made by the Fund \nwill be illiquid and difficult to value, and there will be little or no collateral to protect an investment \nonce made. At the time of the Fund's investment, a portfolio company may lack one or more key \nattributes necessary for success. Many or most of the Fund's portfolio companies will be dependent \nfor their success upon the development, implementation, marketing and customer acceptance of new \ntechnologies that can be rendered obsolete or otherwise unattractive at any time. In most cases, \ninvestments will be long term in nature and may require many years from the date of initial investment \nbefore disposition. It is likely that the Fund will still hold some illiquid securities at the time of the \nFund's dissolution, with the result that such securities may be distributed in-kind or sold for a price \nthat reflects their illiquid nature. \nRisks Related to the Fund's Investment Pipeline \nBiosys has a current pipeline of potential investments that may be suitable for the Fund and that are in \nvarious stages of examination, due diligence review and negotiation (together, the \"Pipeline Deals\"). \nNotwithstanding the Fund's expectations with regard to the Pipeline Deals, until binding transaction \nagreements are signed for such investments and the transactions close, there can be no assurance that \nany Pipeline Deal will become an investment of t\n... [truncated, 3893 chars — for the full page use /api/corpus/document/EFTA00617635/39 or ?id=EFTA00617635&page=39]", "char_count": 3893}, {"efta_number": "EFTA00617635", "page_number": 40, "text_content": "Risks Related to Investments in Emerging Countries \nWhile the General Partner generally intends to cause the Fund to invest in companies based in the \nUnited States, the Fund may also invest in companies based in other countries, including emerging \ncountries that have legal and regulatory environments that are significantly different from those of the \nUnited States or Western Europe. Specifically, investments in such companies may be subject to (i) \neconomic, market, political and local risks related to the governmental systems in such countries, (ii) \nthe risk of nationalization, expropriation, or confiscation of company property by the government; (iii) \nthe risk that future company growth may be limited because the emergence of a domestic consumer \nclass is still at an early stage and because of the country's heavy dependence on exports; (iv) the risk \nthat legal judgments may be more difficult to obtain and/or enforce because the country's legal system \nis still developing; and (v) the risk of acts of terrorism and geopolitical conflict disrupting company \noperations and growth. See also risks related to foreign currency exchange rate fluctuations, —\nFunctional Currency, below. \nRisks Related to Co-Investment \nSubject to the approval of the Advisory Committee and the restrictions set forth in the Partnership \nAgreement, the Fund may co-invest in companies in which the General Partner, the Principals or any \naffiliates of the General Partner or the Principals have previously invested. Because such earlier \ninvestments may have been made at prices and on terms different from those of the Fund's investment, \nthe Fund's investment could be beneficial to the holders of the earlier investments but not to the \nFund. In addition, subject to the approval of the Advisory Committee and the restrictions set forth in \nthe Partnership Agreement, the General Partner may offer the Principals, and/or any affiliates of the \nGeneral Partner or the Principals the opportunity to c\n... [truncated, 3683 chars — for the full page use /api/corpus/document/EFTA00617635/40 or ?id=EFTA00617635&page=40]", "char_count": 3683}, {"efta_number": "EFTA00617635", "page_number": 41, "text_content": "Partner. Transferees will be bound by all applicable provisions of the Partnership Agreement \nincluding, without limitation, provisions governing the transfer of Fund interests. There is no public \nor other market for Fund interests and it is not expected that such a market will develop. \nWithdrawals \nExcept for the mandatory withdrawals for legal reasons, a Limited Partner will not be permitted to \nwithdraw from the Fund or otherwise cease to be a Limited Partner without the consent of the General \nPartner, which consent may be granted or withheld in the General Partner's sole and absolute \ndiscretion. The General Partner may require a Limited Partner to withdraw in whole or in part under \ncircumstances set forth in the Partnership Agreement. \nUpon withdrawal of a Limited Partner, the General Partner generally may (as set forth in greater detail \nin the Partnership Agreement), in its sole discretion, liquidate the withdrawing Limited Partner's Fund \ninterest by: (i) causing the Fund to distribute to the withdrawing Limited Partner, in cash or in kind, \nor by means of a promissory note, a redemption amount equal to the withdrawing Limited Partner's \ncapital account balance (amounts payable in kind generally will be paid ratably in proportion to the \nvalue of each security held by the Fund and may be paid by designating restricted securities to be \ndistributed on a delayed basis); or (ii) selling the withdrawing Limited Partner's Fund interest and \nremitting the proceeds to such withdrawing Limited Partner. \nCompetition \nThe business of investing in healthcare and life sciences companies is highly competitive. The Fund \nand the General Partner will be competing with other new and established funds and investment \norganizations with more substantial resources and experience. Moreover, the volume of attractive \ninvestment opportunities varies greatly from period to period. There can be no assurance that the Fund \nwill be able to make investments on attractive terms, an\n... [truncated, 3388 chars — for the full page use /api/corpus/document/EFTA00617635/41 or ?id=EFTA00617635&page=41]", "char_count": 3388}, {"efta_number": "EFTA00617635", "page_number": 42, "text_content": "Reliance on Key Personnel \nThe success of the Fund is substantially dependent on certain key individuals. Should one or more \nkey individuals become incapacitated or in some other way cease to participate in the Fund, its \nperformance could be adversely affected. \nReliance on Individual Members of the Investment Committee \nThe Fund will be particularly dependent upon the efforts, experience, contacts and skills of the \nindividual members of the Investment Committee. The loss of any such individual could have a \nmaterial, adverse effect on the Fund, and such loss could occur at any time due to death, disability, \nresignation or other reasons. Moreover, the members of the Investment Committee will not be \nrequired to devote their time and attention exclusively to the Fund. Additional persons may be \nadmitted to the Investment Committee at any time and the Limited Partners will have no control over \nthat decision. The Limited Partners will not be permitted to evaluate investment opportunities or \nrelevant business, economic, financial or other information that will be used by the General Partner in \nmaking decisions. \nComposition and Fund Management Experience of the Investment Committee \nSome or all of the members of the Investment Committee may lack substantial prior experience \nmanaging an investment fund such as the Fund and/or working with other Investment Committee \nmembers. There can be no assurance that their experience in making investments through other \nvehicles will result is satisfactory returns for the Fund. \nPrior investments made by the Investment Committee and described in this Memorandum were made \nby such individuals in connection with prior organizations with which they were affiliated. \nAccordingly, the investment performance of such individuals may have benefited from assets of such \norganizations, such as goodwill, proprietary databases, industry contacts and the ability to consult with \ncolleagues. Assets of such other organizations generally wi\n... [truncated, 3226 chars — for the full page use /api/corpus/document/EFTA00617635/42 or ?id=EFTA00617635&page=42]", "char_count": 3226}, {"efta_number": "EFTA00617635", "page_number": 43, "text_content": "While this Memorandum refers to an anticipated investment by entities associated with Bill Gates, \nthere is no guarantee that such entities will ultimately make an investment in the Fund or, if they do, \nthat the Fund will benefit from its association with Mr. Gates. \nIndividuals that are members of the Investment Committee may actually conduct their affairs \n(including, without limitation, their participation in the General Partner) through one or more wealth \nmanagement, estate planning, tax planning, liability limiting or regulatory compliance entities. The \nuse of such entities may, among other potential consequences, limit the ability of the Limited Partners \nto obtain direct recourse against such individuals in the case of breach of any duty or obligation. \nReliance o❑ Third Parties \nThe General Partner and the Fund may require, and rely upon, the services of a variety of third parties, \nincluding but not limited to attorneys, accountants, bankers, brokers, custodians, consultants \n(including \"finders\" and similar persons engaged to assist with the development and exploitation of \nportfolio deal flow, as well as \"experts\" and similar persons engaged to assist with the assessment of \ntechnologies, markets and other matters) and various other persons or agents. The General Partner \nand its affiliated managemenUadvisory entities may also utilize the services of non-executive directors \nwho provide such services on a professional basis and are not primarily part of any single venture \ncapital/private equity firm. Failure by any of these third parties to perform their duties or otherwise \nsatisfy their obligations to the Fund could have a material adverse effect upon the Fund. Except as \notherwise provided in the Fund's Partnership Agreement, the fees and costs associated with such third \nparties will be paid by the Fund. \nLimited Partner Defaults \nLimited Partners generally will not contribute the full amount of their Capital Commitments to the \nFund at the time o\n... [truncated, 3724 chars — for the full page use /api/corpus/document/EFTA00617635/43 or ?id=EFTA00617635&page=43]", "char_count": 3724}, {"efta_number": "EFTA00617635", "page_number": 44, "text_content": "Reserves \nIn managing the Fund, except as otherwise limited under the Partnership Agreement, the General \nPartner may establish reserves for follow-on investments, operating expenses (including Management \nFees payable to the Advisor), Fund liabilities, and other matters. Estimating the amount necessary for \nsuch reserves will be difficult, particularly because follow-on investment opportunities will be directly \ntied to the success and capital needs of portfolio companies. Inadequate or excessive reserves could \nhave a material adverse effect upon the investment returns to the Limited Partners. For example, if \nreserves are inadequate, the Fund may be unable to take advantage of attractive follow-on or other \ninvestment opportunities or to protect its existing investments from dilution. If reserves are excessive, \nthe Fund may decline attractive investment opportunities or hold unnecessary amounts of capital in \nmoney market or similar low-yield accounts. \nDilution \nFollowing the Fund's initial closing, the General Partner will be authorized to admit additional Limited \nPartners (or accept increased Capital Commitments from existing Limited Partners) until the Final \nClosing Date. Except as otherwise provided in the Partnership Agreement, for purposes of allocating \nFund profit and loss, all Capital Commitments made prior to the Final Closing Date will be treated as \nif made at the Fund's initial closing. In consequence, additional Limited Partners (or existing Limited \nPartners that increase their Capital Commitments) may effectively \"buy into\" the Fund during the \nfundraising period at a price that does not necessarily reflect changes in the value of the Fund's assets \nsubsequent to the initial closing. \nConflicts of Interest \nThe Fund will be subject to various potential conflicts of interest. Under certain circumstances, the \nFund may invest in companies in which members of the Investment Committee (including affiliates \nof the General Partner) have a pre-exist\n... [truncated, 3815 chars — for the full page use /api/corpus/document/EFTA00617635/44 or ?id=EFTA00617635&page=44]", "char_count": 3815}, {"efta_number": "EFTA00617635", "page_number": 45, "text_content": "protections for Limited Partners against conflicts of interest faced by the General Partner and the \nInvestment Committee, but will not purport to address all types of conflicts that may arise. Moreover, \nas a practical matter, it may be difficult for Limited Partners to subject the behavior of the General \nPartner and the members of the Investment Committee to close scrutiny. \nUnder the Partnership Agreement, certain transactions that involve conflicts of interest between the \nGeneral Partner and the Fund may be submitted to the Advisory Committee for resolution. However, \nthe Advisory Committee will not necessarily represent the interests of all the Limited Partners and the \nmembers of the Advisory Committee may themselves be subject to various conflicts of interest \n(including as investors in other entities related to Investment Committee members or as participants \nin other investments giving rise to interests that are adverse to the Fund or other Limited Partners). In \ngeneral, the Limited Partners will not be entitled to control the selection of Advisory Committee \nmembers or to review the actions or deliberations of the Advisory Committee. \nDuring the Fund's term, many different types of conflicts of interest may arise and this Memorandum \ndoes not purport to identify all such conflicts. Limited Partners ultimately will be heavily dependent \nupon the good faith of the General Partner and the members of the Investment Committee. \nRisks relating to conflicts of interest are not limited to conflicts affecting the General Partner or \nmembers of the Investment Committee. The Limited Partners are expected to have widely differing \ninterests on a variety of tax, regulatory, business, investment profile and other issues. Certain \nsignificant investors in the Fund have previously invested with the Investment Committee through \nother vehicles. As a result, such investors may have interests that are more allied with the General \nPartner than other Limited Partners. Such\n... [truncated, 4193 chars — for the full page use /api/corpus/document/EFTA00617635/45 or ?id=EFTA00617635&page=45]", "char_count": 4193}, {"efta_number": "EFTA00617635", "page_number": 46, "text_content": "that the considerations identified in this paragraph are not limited to provisions that purport to limit, \nmodify or eliminate fiduciary duties (and, indeed, under specific circumstances, such considerations \nmay apply to nearly every provision of the Fund's Partnership Agreement). \nPlacement Agents \nThe General Partner in the future may agree to compensate one or more third parties facilitating \ninvestments in the Fund. Such compensation to a placement agent or such third parties (\"Placement \nFee\") may be based on the Capital Commitments of the Limited Partners and investment \nrepresentatives of a placement agent or such third parties will have an incentive to recommend the \nFund interests to prospective investors. Employees of a placement agent or such third parties may be \ndirectly compensated based on an investor's decision to invest in the Fund interests. \nIf a Placement Fee is payable with respect to a potential investor, such investor may receive additional \ndisclosures about the placement agent or third party facilitating investments in the Fund and the \narrangements with such placement agent or third party in a supplement to this Memorandum. \nEconomic Interest of General Partner \nBecause the percentage of profits distributed to the General Partner will exceed the capital contribution \npercentage of the General Partner, the General Partner may have an incentive to make investments \nthat are riskier or more speculative than if the General Partner received allocations on a basis identical \nto that of the Limited Partners or were compensated on a basis not tied to the performance of the Fund. \nSide Agreements \nIn accordance with common industry practice, the General Partner may enter into one or more \"side \nletters\" or similar agreements with certain Limited Partners pursuant to which the General Partner \ngrants to such Limited Partners specific rights, benefits or privileges that are not made available to \nLimited Partners generally. Such side letters may gran\n... [truncated, 3133 chars — for the full page use /api/corpus/document/EFTA00617635/46 or ?id=EFTA00617635&page=46]", "char_count": 3133}, {"efta_number": "EFTA00617635", "page_number": 47, "text_content": "Distributions in Kind \nAlthough the General Partner intends to distribute cash rather than marketable securities, the Fund \nmay from time to time distribute portfolio company marketable securities to the Partners. Except as \nspecifically provided in the Fund's Partnership Agreement, such distributions will be made solely at \nthe discretion of the General Partner. \nDistributed securities may be subject to a variety of legal or practical limitations on sale. In particular, \nimmediately following a distribution of securities, trading volume may be insufficient to support sales \nby the Partners without such sales triggering a price decline which makes it difficult or impossible for \nall Partners to sell such securities at the distribution price. Nevertheless, the distribution price of such \nsecurities will be established under the provisions of the Fund's Partnership Agreement and will not \nbe adjusted to reflect actual sale prices obtained by the Partners. \nNo Assurance of Confidentiality \nAs part of the subscription process and otherwise in their capacity as Limited Partners, investors will \nprovide significant amounts of information about themselves to the General Partner and the Fund. \nUnder the terms of the Fund's Partnership Agreement as well as applicable laws, such information \nmay be made available to other Limited Partners, third parties that have dealings with the Fund, and \ngovernmental authorities (including by means of securities laws-required information statements that \nare open to public inspection). \nConcentration of Investments \nThe Fund's portfolio will be concentrated in a limited number of companies in the healthcare and life \nsciences sector, increasing the vulnerability of the portfolio as compared with a portfolio that is more \ndiversified over a larger number of companies and industries. \nFunctional Currency \nThe functional currency of the Fund will be U.S. dollars. Capital commitments of the Partners, capital \ncontributions, and distributions \n... [truncated, 3007 chars — for the full page use /api/corpus/document/EFTA00617635/47 or ?id=EFTA00617635&page=47]", "char_count": 3007}, {"efta_number": "EFTA00617635", "page_number": 48, "text_content": "Limited or No Control over Portfolio Companies \nThe General Partner generally will not seek control over the management of the portfolio companies \nin which the Fund invests, and the success of each investment generally will depend on the ability, \nexpertise and success of the company founder(s) and other senior management of the portfolio \ncompany. The Fund will often invest in companies in which other private investment funds have made \nequity investments. In many cases, the Fund typically may not have the right to designate a member \nof the board of directors of its portfolio companies, with the result that other investors may have more \ninfluence in decisions made by and affecting portfolio companies. In some instances, the Fund will \ngrant a proxy to vote its securities to portfolio company founders or chief executive officers. The mere \nfact that the General Partner disagrees with decisions made by other investors in a portfolio company \nlikely will not trigger any particular ability of the Fund to dispose of its investment in such portfolio \ncompany, with the result that the value of the Fund's investment in a portfolio company may be \nmaterially impacted by the decisions of other investors. The Fund's portfolio companies will face a \nnumber of business challenges, risks and uncertainties, with respect to which the Fund will be entirely \ndependent on company management. Conversely, the Fund's Partnership Agreement will not require \nthat members of the General Partner serve as officers or directors of portfolio companies, and there \ncan be no assurance that the General Partner will have a legal right to influence the management of \nany portfolio company or companies. \nMaterial Non-Public Information \nBy virtue of the Fund's status as a significant shareholder of a portfolio company, or in their capacity \nas directors of a portfolio company, members of the Investment Committee may become subject to \nduties which adversely affect the Fund. For example, the Fund \n... [truncated, 3810 chars — for the full page use /api/corpus/document/EFTA00617635/48 or ?id=EFTA00617635&page=48]", "char_count": 3810}, {"efta_number": "EFTA00617635", "page_number": 49, "text_content": "General Partner, or the members of the Investment Committee may be named as defendants. Under \nmost circumstances, the Fund will indemnify the General Partner and Investment Committee members \nfor any costs they incur in connection with such disputes. Beyond direct costs, such disputes may \nadversely affect the Fund in a variety of ways, including by distracting the General Partner and \nharming relationships between the Fund and its portfolio companies or other investors in such portfolio \ncompanies. \nTo the extent set forth in the Fund's Partnership Agreement, Limited Partners may be required to \nreturn distributions previously received by them from the Fund in order to enable the Fund to make \nindemnification payments to indemnified persons. \nMore generally, Limited Partners may be required to return distributions previously received by them \nfrom the Fund to the extent required by applicable law. Such a return obligation may occur, for \nexample, if the Fund makes a distribution at a time when it is technically insolvent or otherwise unable \nto satisfy the claims of creditors. \nOverall, the multinational nature of the Fund and its related parties may make litigation more complex \nand costly, and may limit the effectiveness and/or enforceability of legal judgments. \nRegulatory Concerns \nThe Fund will be subject to a variety of securities laws and other types of governmental regulation \nthat may limit the scope of its operations or impose material compliance costs and other burdens. \nWhile the General Partner believes that the Fund will not be subject to the registration requirements \nof the U.S. Investment Company Act of 1940, as amended (the \"Investment Company Act\"), there can \nbe no assurance that this belief is, or will continue to be, correct. If the Fund were subject to such \nregistration requirements, the Fund's performance could be materially adversely affected. \nThe General Partner is not registered as an investment adviser, or included within the registra\n... [truncated, 3501 chars — for the full page use /api/corpus/document/EFTA00617635/49 or ?id=EFTA00617635&page=49]", "char_count": 3501}, {"efta_number": "EFTA00617635", "page_number": 50, "text_content": "guarantees of portfolio company indebtedness. Similarly, the General Partner may cause the Fund to \ndispose of disqualifying assets earlier than otherwise would be the case. Thus, as an overall matter, \nthe Fund may experience materially less flexibility in the conduct of its affairs relative to a fund that \ndoes not seek to qualify as a \"venture capital fund.\" The General Partner similarly may elect to qualify \nthe Fund under corresponding provisions of other applicable laws, thereby giving rise to corresponding \nconsiderations in respect of such other laws. \nFor the avoidance of doubt, and without regard to the General Partner's status under the Advisers Act \nor any other laws, the General Partner hereby provides notice that the Fund is intended and expected \nto pursue a venture capital strategy. Any references in this Memorandum or otherwise to the Fund as \nhaving \"private equity\" attributes are intended solely to address customary usage that places \"venture \ncapital\" within the broader range of \"private equity\" and are not intended to indicate that the Fund will \npursue a strategy other than a venture capital strategy. \nThe General Partner is not registered, and believes that it is not otherwise regulated, as a commodity \npool operator under rules issued by the United States Commodity Futures Trading Commission (the \n\"CFTC\"). Accordingly, the General Partner believes that it generally is not subject to certain \nrestrictions, disclosure requirements and other obligations applicable to registered or unregistered \ncommodity pool operators under CFTC rules, although the General Partner may become subject to \nsuch restrictions, requirements and obligations in the future. Under the Fund's Partnership Agreement, \nthe General Partner will be authorized to manage and conduct the affairs of the Fund in a manner that \n(i) avoids classification of the Fund as a commodity pool and/or (ii) qualifies the General Partner for \nexemption from registration as a commodity pool oper\n... [truncated, 3879 chars — for the full page use /api/corpus/document/EFTA00617635/50 or ?id=EFTA00617635&page=50]", "char_count": 3879}, {"efta_number": "EFTA00617635", "page_number": 51, "text_content": "Limited Access to Information \nThe rights of Limited Partners to information regarding the Fund and its portfolio companies will be \nspecified, and strictly limited, in the Fund's Partnership Agreement. In particular, it is anticipated that \nthe General Partner will obtain certain types of material information that will not be disclosed to \nLimited Partners. For example, the General Partner may obtain information regarding portfolio \ncompanies (e.g., via members of the Investment Committee serving as advisors to, or officers/directors \nof, portfolio companies) that is material to determining the value of securities issued by such portfolio \ncompanies. Such information may be withheld from Limited Partners in order to comply with duties \nto such portfolio companies or otherwise to protect the interests of such portfolio companies or the \nFund. \nDecisions by the General Partner to withhold information may have adverse consequences for Limited \nPartners in a variety of circumstances. For example: (a) a Limited Partner that seeks to sell its interest \nin the Fund may have difficulty in determining an appropriate price for such interest; (b) decisions by \nthe General Partner to withhold information may make it difficult for Limited Partners to subject the \nGeneral Partner to rigorous oversight; and (c) each communication from the General Partner to one or \nmore Limited Partners must be interpreted in light of the realistic possibility that the General Partner \nis in possession of undisclosed information relating to the Fund or its portfolio companies that could \nbe material to a comprehensive assessment of such communication. Overall, prospective Investors \nshould not expect the Fund to be operated with the same degree of \"transparency\" as a publicly traded \ncorporation. \nExculpation and Indemnification \nThe Fund's Partnership Agreement will contain provisions that relieve the General Partner and \nmembers of the Investment Committee, members of the Advisory Committee, an\n... [truncated, 3580 chars — for the full page use /api/corpus/document/EFTA00617635/51 or ?id=EFTA00617635&page=51]", "char_count": 3580}, {"efta_number": "EFTA00617635", "page_number": 52, "text_content": "Taxation \nRisks associated with tax matters are discussed below under the heading \"Certain Material U.S. \nFederal Income Tax Considerations,\" which prospective investors should read carefully. Prospective \ninvestors are urged to consult their own tax advisors with respect to their own tax situations and the \neffects of an investment in the Fund. \nThis Memorandum does not contain tax disclosure relating to potential home jurisdictions of the \nFund's portfolio companies. Moreover, tax laws change on a frequent and unpredictable basis. \nProspective investors should assume that home tax laws will have a significant impact upon the \noperations and financial performance of the Fund and may even impose direct obligations (such as \nreturn filing obligations) upon Limited Partners. \nERISA \nEach prospective employee benefit plan investor is urged to read the section entitled \"Certain ERISA \nConsiderations\" below and consult with its own legal counsel regarding ERISA matters. Without \nlimitation, a prospective investor that is a fiduciary under ERISA should carefully consider whether \nan investment in the Fund would be consistent with its fiduciary duties. \nLegal Counsel \nDocuments relating to the Fund, including the subscription agreement to be completed by each \ninvestor as well as the Fund's Partnership Agreement, will be detailed and often technical in nature. \nLegal counsel to the Fund will represent the interests solely of the General Partner and the Fund, and \nwill not represent the interests of any investor. Moreover, under the Fund's Partnership Agreement, \neach investor will be required to waive any actual or potential conflicts of interest between such \ninvestor and legal counsel to the Fund. Accordingly, each investor is urged to consult with its own \nlegal counsel before investing in the Fund or making any other decisions regarding Fund matters. \nIn advising as to matters of law (including matters of law described in this Memorandum), legal \ncounsel to the Fund ha\n... [truncated, 3398 chars — for the full page use /api/corpus/document/EFTA00617635/52 or ?id=EFTA00617635&page=52]", "char_count": 3398}, {"efta_number": "EFTA00617635", "page_number": 53, "text_content": "been consulted by the General Partner. There may exist other matters that could have a bearing on the \nFund as to which Locke Lord has not been consulted. In addition, Locke Lord does not undertake to \nmonitor compliance by the General Partner and its affiliates with the investment program, valuation \nprocedures and other guidelines set forth herein, nor does Locke Lord monitor ongoing compliance \nwith applicable laws. In the course of advising the General Partner, there are times when the interests \nof the Limited Partners may differ from those of the General Partner and the Fund. Locke Lord does \nnot represent the Limited Partners' interests in resolving these issues. In reviewing this Memorandum, \nLocke Lord has relied upon information furnished to it by the General Partner and has not investigated \nor verified the accuracy and completeness of information set forth herein concerning the Fund. \nFactual Statements/Track Record Information \nCertain of the factual statements made in this Memorandum are based upon information from various \nsources believed by the General Partner to be reliable. The General Partner and the Fund have not \nindependently verified any of such information and shall have no liability for any inaccuracy or \ninadequacy thereof. No party (including legal counsel to the Fund and the General Partner) has been \nengaged to verify the accuracy or adequacy of any of the factual statements contained in this \nMemorandum. In particular, neither legal counsel nor any other party has been engaged to verify any \nstatements relating to the experience, track record, skills, contacts or other attributes of the members \nof the Investment Committee or to the anticipated future performance of the Fund. \nInvestors are cautioned about relying upon information within this Memorandum that presents, or is \nbased upon, valuations of private company securities or securities that are otherwise subject to \nlimitations on marketability (such as underwriters' lock-ups or r\n... [truncated, 3915 chars — for the full page use /api/corpus/document/EFTA00617635/53 or ?id=EFTA00617635&page=53]", "char_count": 3915}, {"efta_number": "EFTA00617635", "page_number": 54, "text_content": "\"Gross IRRs\" and \"Gross Multiples\" do not reflect any fees, expenses and carried interest payable, \nwhich may be substantial. \nDuring the term of the Fund, the General Partner will provide to the Limited Partners reports and other \ninformation regarding the condition and prospects of the Fund and its portfolio companies. The \nGeneral Partner's duties, obligations and liability to the Limited Partners with respect to the content, \ncompleteness and accuracy of such information will be determined solely under the Fund's Partnership \nAgreement. \nDefinitive Terms and Conditions \nPortions of this Memorandum describe specific terms and conditions expected to be set forth in the \nFund's Partnership Agreement. The actual terms and conditions set forth in the Partnership Agreement \nmay vary materially from those described in this Memorandum for a variety of reasons including \nnegotiations between the General Partner and prospective Limited Partners prior to the Fund's initial \nclosing as well as formal amendments to the Partnership Agreement following such closing. \nMoreover, the Partnership Agreement will contain highly detailed terms and conditions, many of \nwhich are not described fully (or at all) in this Memorandum. In all cases, the Fund's Partnership \nAgreement will supersede this Memorandum. Prospective investors are urged to carefully review the \nFund's Partnership Agreement and the rules governing amendments set forth in the Partnership \nAgreement. \nDeemed Consent Upon Failure to Respond \nPursuant to the Fund's subscription agreement, a person subscribing for an interest in the Fund \ngenerally authorizes the General Partner to execute the Fund's definitive Partnership Agreement on \nthe investor's behalf. It is possible that (due to negotiation with other investors or otherwise) the \nprecise terms and conditions of the Partnership Agreement may be modified between the date on which \nan investor executes and delivers its subscription agreement and the date of the Fund\n... [truncated, 3494 chars — for the full page use /api/corpus/document/EFTA00617635/54 or ?id=EFTA00617635&page=54]", "char_count": 3494}, {"efta_number": "EFTA00617635", "page_number": 55, "text_content": "\"managing partners\" or \"general partners\" even though they are not actually partners of any \npartnership. The Fund is a limited partnership, the General Partner of the Fund is a limited company \nand individuals participating in the management of the Fund through the General Partner will be \nmembers of such limited company. It is not intended that the Fund will have any general partner other \nthan the General Partner or that any actual general partnership will in any manner be associated with \nthe formation, operation, dissolution or termination of the Fund. Prospective investors must not \npresume or rely upon the existence of any actual legal entities other than the Fund and the General \nPartner. With respect to all matters involving industry specific terminology, prospective investors are \nurged to consult with their own legal and other advisors. \nAdditional Risks for Investors in Second or Later Closings \nOn or before the Final Closing Date, the Fund may admit additional Limited Partners or accept \nincreased Capital Commitments from existing Limited Partners at one or more additional closings. \nExcept as otherwise provided in the Partnership Agreement, the fact that certain Capital Commitments \nmay be attributable to closings held after the initial closing will generally be disregarded for purposes \nof allocating Fund profits and losses (i.e., all Capital Commitments will be treated as if made at the \ninitial closing). \nExcept as otherwise provided in the Partnership Agreement, a Limited Partner that is admitted to the \nFund, or increases its Capital Commitment, after the initial closing will be required to immediately \ncontribute that portion of its entire Capital Commitment that it would have been required to contribute \nif such entire Capital Commitment had been made at the initial closing. In addition, under the \nconditions described in the Summary of Principal Terms of the Fund above, a later-admitted Limited \nPartner may be required \"buy-in\" to Fund investme\n... [truncated, 4127 chars — for the full page use /api/corpus/document/EFTA00617635/55 or ?id=EFTA00617635&page=55]", "char_count": 4127}, {"efta_number": "EFTA00617635", "page_number": 56, "text_content": "obligation to update this Memorandum to include (or otherwise inform prospective investors of) any \nsuch information. \nUnder some circumstances, a person considering an investment in the Fund may be provided with \ncopies of the Fund's financial statements for periods following the initial closing. Any such person is \ncautioned that it will be inherently difficult to determine the value of private company securities held \nby the Fund and that, accordingly, it would be inappropriate to interpret any information set forth in \nsuch statements as a representation or warranty regarding the true fair market value of any such \nsecurities. \nAdditional Risks for Investors in Parallel Funds \nReferences in this Memorandum to the \"Fund\" are to Biosys Capital Partners, LP, a Delaware limited \npartnership (the \"Delaware Partnership\"). In addition, the General Partner or an affiliate may organize \none or more limited partnerships, other investment vehicles, other investment advisory programs or \nother entities to invest in parallel with the Delaware Partnership in order to facilitate investment by \ncertain investors (depending on applicable legal and/or tax requirements). These parallel investment \nvehicles may be created with a legal structure which may be the same or different from that of the \nother Parallel Funds, but will have substantially the same economic terms. \nEach of the Parallel Funds will generally invest proportionately, based on their respective Capital \nCommitments, in all investments, on substantially the same terms and conditions subject to any \nrestrictions applicable to such Parallel Fund. \nThe General Partner may also form, or consent to the formation of, special purpose entities to invest \nin the Fund (\"Feeder Funds\"), which will invest on the same terms as other Limited Partners, except \nfor certain \"look-through\" provisions relating to voting, exceptions to the obligation to make capital \ncontributions, and default. \nInvestors in Parallel Funds are cautione\n... [truncated, 3344 chars — for the full page use /api/corpus/document/EFTA00617635/56 or ?id=EFTA00617635&page=56]", "char_count": 3344}, {"efta_number": "EFTA00617635", "page_number": 57, "text_content": "the Feeder Funds' assets will be bonded to the extent required by ERISA and prohibited from \nexercising discretion to cause the Fund to engage in transactions with affiliates of the General Partner. \nWhen Investing in the Fund through a feeder fund, each Partner subject to ERISA will, by making a \ncapital contribution to the feeder fund, be deemed to direct the General Partner or manager of the \nfeeder fund to invest the amount of such capital contribution in the Fund and acknowledge that during \nany period when the underlying assets of the feeder fund are deemed to constitute \"plan assets\" under \nERISA, the General Partner, or manager of the feeder fund will act as a custodian with respect to the \nassets of such Partner but is not intended to be a fiduciary for purposes of ERISA. Prospective Limited \nPartners subject to ERISA should refer to Section VIII — Certain Tax and ERISA Considerations. \nProspective Limited Partners such as pension funds that are subject to the provisions of ERISA should \nconsult with their counsel and advisors as to the provisions of ERISA applicable to an investment in \nthe Fund. \nSTRICTLY CONFIDENTIAL \n53 \nDRAFT - Jeffery Epstein \nEFTA00617692\n", "char_count": 1190}, {"efta_number": "EFTA00617635", "page_number": 58, "text_content": "VIII. CERTAIN TAX AND ERISA CONSIDERATIONS \nCertain Material U.S. Federal Income Tax Considerations \nFor the purposes of the following discussion, references to the \"Partnership\" shall mean the Fund, \nwhich is organized as a Delaware limited partnership. Investors participating in a Parallel Fund \nother than the Fund should consult their own tax advisers. \nThe following summary outlines certain material U.S. federal income tax considerations relating to an \ninvestment in the Partnership by U.S. Investors (as defined herein) and, to a limited extent, Non-U.S. \nInvestors (as defined herein). This summary does not contain a complete discussion of the federal tax \naspects of an investment in the Partnership and is intended only to provide general information for \ninvestors that hold their interests in the Partnership as a capital asset and is not intended as a substitute \nfor careful tax planning. This summary does not address the tax considerations that may be relevant \nto investors subject to special treatment under the Internal Revenue Code of 1986, as amended (the \n\"Code\"), including, without limitation, U.S. expatriates, brokers or dealers in securities, tax-exempt \nentities (except to the limited extent discussed below), regulated investment companies, real estate \ninvestment trusts, insurance companies, personal holding companies, or persons who acquire an \ninterest in the Partnership in connection with the performance of services. Such persons should consult \nwith their own tax advisors as to the U.S. federal income tax consequences of an investment in the \nPartnership, which may differ substantially from those described herein. This summary also does not \naddress any U.S. estate, alternative minimum, state or local, or foreign (except to the limited extent \ndiscussed below) tax consequences of an investment in the Partnership. If a partnership owns an \ninterest in the Partnership, the tax treatment of a partner in such partnership generally will depend \nupon th\n... [truncated, 3919 chars — for the full page use /api/corpus/document/EFTA00617635/58 or ?id=EFTA00617635&page=58]", "char_count": 3919}, {"efta_number": "EFTA00617635", "page_number": 59, "text_content": "positions taken by the Partnership and that, if challenged by the IRS, the Partnership's tax positions \nmight not be sustained by the courts. \nIn view of the foregoing, each prospective investor should consult its own tax advisor regarding all U.S. \nfederal, state, local and foreign income and other tax consequences of an investment in the Partnership, with \nspecific reference to such investor's own particular tax situation and recent changes in applicable law. \nPartnership Status \nIt is intended that the Partnership will be treated for U.S. federal income tax purposes as a partnership \nand not as an association, taxable mortgage pool or publicly traded partnership (a \"PTP\") taxable as a \ncorporation. A partnership is a PTP if interests in the partnership are traded on an established securities \nmarket or are readily tradable on a secondary market. The General Partner intends to operate the \nPartnership so it will not be treated as a PTP. The Partnership intends to obtain and rely on appropriate \nrepresentations and undertakings from each Limited Partner in order to ensure that the Partnership is \nnot treated as a PTP. \nThe discussion below assumes that the Partnership will be treated as a partnership for U.S. federal \nincome tax purposes. No application has been or is contemplated to be made to the IRS for a ruling \non the classification of the Partnership for U.S. federal income tax purposes. \nTaxation of Partnership and Limited Partners \nAs a partnership, the Partnership is not itself subject to U.S. federal income tax. Each Partner will be \nrequired to take into account, in the Partner's taxable year during which a taxable year of the \nPartnership ends such Partner's distributive share of all items of Partnership income, gain, loss, \ndeduction, or credit for such taxable year of the Partnership. A Partner must take such items into \naccount even if the Partnership does not make any distributions to such Partner during its taxable year. \nConsequently, a Limited Pa\n... [truncated, 3548 chars — for the full page use /api/corpus/document/EFTA00617635/59 or ?id=EFTA00617635&page=59]", "char_count": 3548}, {"efta_number": "EFTA00617635", "page_number": 60, "text_content": "The Partnership generally intends to take the position for U.S. federal income tax purposes that its \noperations and activities constitute an investment activity rather than the active conduct of a trade or \nbusiness. As a result, the Management Fee, together with certain other Partnership expenses, will \nlikely be treated as \"miscellaneous itemized deductions\" of the Partnership for U.S. federal income \ntax purposes. For U.S. federal income tax purposes, individuals and certain trusts and estates that hold \ninterests in the Partnership may deduct such expenses in a taxable year only to the extent that their \naggregate miscellaneous itemized deductions for the year exceed 2% of their adjusted gross incomes \nfor the year. Thus, in the case of certain Limited Partners, all or a portion of the above expenses may \nnot be deductible in certain taxable years. \nIn addition, individuals, estates and trusts are now subject to a Medicare tax of 3.8% on \"net investment \nincome\" (or undistributed \"net investment income,\" in the case of estates and trusts) for each taxable \nyear, with such tax applying to the lesser of such income or the excess of a person's adjusted gross \nincome (with certain adjustments) over a specified threshold ($250,000 for married individuals filing \njointly; $125,000 for married individuals filing separately and $200,000 for other individuals). Net \ninvestment income includes net income from interest, dividends, annuities, royalties, rents and net \ngain attributable to the disposition of investment property. It is anticipated that net income and gain \nattributable to an investment in or disposition of interests in the Partnership will be included in a \nPartner's \"net investment income.\" Prospective investors should consult their own tax advisors \nregarding the impact of the 3.8% Medicare tax. \nConsiderations Regarding Non-U.S. Investments \nThe Partnership may own stock or securities of non-U.S. corporations. The discussion below is only \na brief summary\n... [truncated, 3684 chars — for the full page use /api/corpus/document/EFTA00617635/60 or ?id=EFTA00617635&page=60]", "char_count": 3684}, {"efta_number": "EFTA00617635", "page_number": 61, "text_content": "Foreign Tax Credit Limitations \nThe Partnership's income or gains may be subject to withholding, net income or other taxation in \njurisdictions where the investments are located; the applicability of any such taxes are not addressed \nin this Memorandum. \nWith respect to creditable foreign taxes paid on the income or gains of the Partnership, U.S. Investors \nmay be entitled to claim either a foreign tax credit, or, subject to limits generally applicable to all \ndeductions, a deduction for their share of such foreign taxes. However, the rules for determining \neligibility for and limits on foreign tax credits are extremely complex and depend on a number of \nfactors that are unique to each U.S. Investor's particular circumstances. For example, a credit for \nforeign taxes is subject to the limitation that it may not exceed the U.S. Investor's federal tax (before \nthe credit) attributable to its total foreign source income in the relevant category. Furthermore, foreign \ntaxes paid by a foreign corporation in which the Partnership holds a direct or indirect equity investment \ngenerally cannot be claimed as a credit by a U.S. Investor unless the U.S. Investor is a corporation that \nis treated as owning (actually or constructively) at least 10% of the voting stock of the foreign \ncorporation and certain other conditions are satisfied. U.S. Investors should consult with their own tax \nadvisors regarding all aspects of the rules applicable to foreign tax credits and the potential availability \nof foreign tax credits to them with respect to the income or taxes of the Partnership. \nTax-Exempt Investors \nA U.S. Investor that is a tax-exempt entity is generally exempt from U.S. federal income tax on its \nincome, except to the extent of its unrelated business taxable income (\"UBTI\"). UBTI is defined \ngenerally as the gross income derived from any trade or business that is regularly carried on by the \ntax-exempt entity and unrelated to its exempt purposes, less any directly connecte\n... [truncated, 3429 chars — for the full page use /api/corpus/document/EFTA00617635/61 or ?id=EFTA00617635&page=61]", "char_count": 3429}, {"efta_number": "EFTA00617635", "page_number": 62, "text_content": "Non-U.S. Investors \nThe federal income tax treatment of a Non-U.S. Investor investing in the Partnership is complex and \nwill vary depending upon the circumstances of the Non-U.S. Investor and the activities of the \nPartnership. If the Partnership is deemed to be engaged in a U.S. trade or business, then a Non-U.S. \nInvestor will be subject to federal income tax each year on its distributive share of the taxable income \nof the Partnership deemed to be effectively connected with a U.S. trade or business (\"ECI\"), as if such \ninvestor were a U.S. person, regardless of whether the Partnership makes any cash distributions (and \ncertain corporate Non-U.S. Investors could be subject to an additional 30% branch profits tax, subject \nto reduction by treaty). The Non-U.S. Investor will also be required to file a U.S. federal income tax \nreturn. The Partnership will be required to withhold, generally at the highest graduated rate that the \nNon-U.S. Investor would be subject to if the investor were a U.S. person, on a Non-U.S. Investor's \nallocable share of any taxable income of the Partnership that is ECI (whether or not such income is \ndistributed). Such withholding tax may be claimed as a credit against such Non-U.S. Investor's \nsubstantive U.S. tax liability. Non-U.S. Investors should be aware that the Partnership anticipates that \nit will be engaged in a U.S. trade or business and that it will incur ECI. \nIn addition, to the extent that the Partnership realizes U.S. source fixed, determinable, annual or \nperiodical income (such as U.S. source interest and dividend income) that is not ECI, the Non-U.S. \nInvestor's allocable share of such income generally will be subject to a 30% withholding tax unless \nthe Non-U.S. Investor completes and files Form W-8ECI (Certificate of Foreign Person's Claim for \nExemption from Withholding on Income Effectively Connected with the Conduct of a Trade or \nBusiness in the United States). This form must be filed with the Partnership annually f\n... [truncated, 4199 chars — for the full page use /api/corpus/document/EFTA00617635/62 or ?id=EFTA00617635&page=62]", "char_count": 4199}, {"efta_number": "EFTA00617635", "page_number": 63, "text_content": "currently does not intend to acquire or dispose of assets that qualify as United States real property \ninterests, there can be no assurance that shares of portfolio company stock will not so qualify. \nNon-U.S. Investors intending to rely on a tax treaty between the U.S. and their jurisdiction of residence \nshould also be aware that there are various limitations, both under U.S. domestic law and certain tax \ntreaties, on the ability of a Non-U.S. Investor to claim the benefits of a tax treaty. \nNon-U.S. Investors generally will be personally liable to the Partnership with respect to any \nwithholding tax not satisfied out of their share of any distributions by the Partnership. \nEach Non-U.S. Investor is urged to consult with its own tax advisers regarding U.S. federal, state \nand local and foreign tax treatment of an investment in the Partnership. \nPartner Information Reporting Requirements \nThe U.S. tax rules impose certain information reporting requirements on U.S. Investors who (a) own, \ndirectly or indirectly, more than certain threshold amounts of capital interests or profits interests in \nforeign entities treated as partnerships for U.S. federal income tax purposes, such as the Partnership \nor a foreign company into which the Partnership invests, or (b) contribute, in their capacity as partners, \nmore than $100,000 to a non-U.S. partnership, such as the Partnership or a foreign company into which \nthe Partnership invests, during any twelve-month period, or (c) hold certain assets, including \n\"specified foreign financial assets\" (which include interests in non-U.S. entities such as the \nPartnership), in excess of certain threshold amounts. In certain circumstances, U.S. Investors may be \nrequired to file reports annually. \nOther Reporting and Withholding Requirements \nThe Foreign Account Tax Compliance Act (\"FATCA\"), imposes withholding taxes on certain types \nof payments made to \"foreign financial institutions\" and certain other non-U.S. entities unless \nadditio\n... [truncated, 3477 chars — for the full page use /api/corpus/document/EFTA00617635/63 or ?id=EFTA00617635&page=63]", "char_count": 3477}, {"efta_number": "EFTA00617635", "page_number": 64, "text_content": "In addition to the U.S. federal income tax consequences described above, prospective investors should consider \npotential non-U.S. and U.S. state and local tax consequences of an investment in the Partnership, including the \nlikelihood that investors will be required to file tax returns and pay tax in jurisdictions where the Partnership, \nits subsidiaries, or portfolio companies hold real property, do business or are organized. The Partnership and \nother entities through which it invests may be subject to non-U.S. and U.S. state or local income or similar \ntaxes, including non-U.S. and U.S. state or local tax withholding or reporting requirements. \nProspective investors should consult their own tax advisers for further information about U.S. \nfederal, state and local, non-U.S. and other tax consequences of investing in the Partnership. \nSTRICTLY CONFIDENTIAL \n60 \nDRAFT - Jeffery Epstein \nEFTA00617699\n", "char_count": 914}, {"efta_number": "EFTA00617635", "page_number": 65, "text_content": "Certain ERISA Considerations \nThe advice set forth below was not intended or written to be used, and it cannot be used, by any \ntaxpayer for the purpose of avoiding United States federal tax penalties that may be imposed on \nthe taxpayer. \nThe advice was written to support the promotion or marketing of the \ntransaction(s) or matter(s) addressed herein. Each taxpayer should seek advice based upon the \ntaxpayer's particular circumstances from an independent tax advisor. The foregoing language \nis intended to satisfy the requirements under the regulations in Section 10.35 of Circular 230. \nThe United States Employee Retirement Income Security Act of 1974, as amended (\"ERISA\"), \nimposes certain requirements on employee benefit plans (as defined in Section 3(3) of ERISA) subject \nto the provisions of Title I of ERISA, including entities such as collective investment funds and \nseparate accounts whose underlying assets include the assets of such plans (collectively, \"ERISA \nPlans\"), and on those persons who are fiduciaries with respect to ERISA Plans. Investments by ERISA \nPlans are subject to ERISA's general fiduciary requirements, including the requirement of investment \nprudence and diversification. In addition, ERISA requires the fiduciary of an ERISA Plan to maintain \nthe indicia of ownership of the ERISA Plan's assets within the jurisdiction of the United States district \ncourts. The prudence of a particular investment must be determined by the responsible fiduciary of \nan ERISA Plan by taking into account the ERISA Plan's particular circumstances and all of the facts \nand circumstances of the investment including, but not limited to, the matters discussed above under \n\"Investment Strategy,\" the fact that the Fund has no history of operations, none of the Fund's \ninvestments have been selected as of the date of the Memorandum and the fact that in the future there \nmay be no market in which such fiduciary will be able to sell or otherwise dispose of Interests. \nSecti\n... [truncated, 3894 chars — for the full page use /api/corpus/document/EFTA00617635/65 or ?id=EFTA00617635&page=65]", "char_count": 3894}, {"efta_number": "EFTA00617635", "page_number": 66, "text_content": "is treated as indebtedness under applicable local law and which has no substantial equity features) that \nis neither a \"publicly offered security\" nor a security issued by an investment company registered \nunder the Investment Company Act, the Plan's assets include both the equity interest and an undivided \ninterest in each of the entity's underlying assets, unless it is established that the entity is an \"operating \ncompany\" or that \"benefit plan investors\" hold less than 25% of the equity interests in the entity. The \nInterests in the Fund would constitute an \"equity interest\" in the Fund for purposes of the Plan Assets \nRegulation, and the Interests will not constitute \"publicly offered securities\" for purposes of the Plan \nAssets Regulation. In addition, the Fund will not be registered under the Investment Company Act. \nThe 25% Limit. Under the Plan Assets Regulation, and assuming no other exemption applies, an \nentity's assets would be deemed to include \"plan assets\" subject to ERISA on any date if, immediately \nafter the most recent acquisition of any equity interest in the entity, 25% or more of the value of any \nclass of equity interests in the entity is held by \"benefit plan investors\" (the \"25% Limit\"). For \npurposes of this determination, the value of equity interests held by a person (other than a benefit plan \ninvestor) that has discretionary authority or control with respect to the assets of the entity or that \nprovides investment advice for a fee with respect to such assets (or any affiliate of such a person) is \ndisregarded. The term \"benefit plan investor\" is defined in the Plan Assets Regulation as (a) any \nemployee benefit plan (as defined in Section 3(3) of ERISA) that is subject to the provisions of Title I \nof ERISA, (b) any plan that is subject to Section 4975 of the Code and (c) any entity whose underlying \nassets include plan assets by reason of a plan's investment in the entity (to the extent of such plan's \ninvestment in the entity). Thus, \n... [truncated, 4216 chars — for the full page use /api/corpus/document/EFTA00617635/66 or ?id=EFTA00617635&page=66]", "char_count": 4216}, {"efta_number": "EFTA00617635", "page_number": 67, "text_content": "the assets of the Fund from being treated as assets of any investing Plan for purposes of the Plan Assets \nRegulation. Accordingly, the General Partner believes, on the basis of the Plan Assets Regulation, \nthat the underlying assets of the Fund should not constitute \"plan assets\" for purposes of ERISA. \nHowever, no assurance can be given that this will be the case. \nIf the Fund's assets are deemed to constitute \"plan assets\" under ERISA, certain of the transactions in \nwhich the Fund might normally engage could constitute a non-exempt \"prohibited transaction\" under \nERISA or Section 4975 of the Code. In such circumstances, the General Partner, in its sole discretion, \nmay void or undo any such prohibited transaction, and may require each Limited Partner that is a \n\"benefit plan investor\" to withdraw from the Fund upon terms that the General Partner considers \nappropriate. In addition, if the Fund's assets are deemed to be \"plan assets,\" the General Partner may \nbe considered to be a fiduciary under ERISA. \nA fiduciary of an ERISA plan or other plan that proposes to cause such entity to purchase an Interest \nshould consult with its counsel regarding the applicability of the fiduciary responsibility and prohibited \ntransaction provisions of ERISA and Section 4975 of the Code to such an investment, and to confirm \nthat such investment will not constitute or result in a non-exempt prohibited transaction or any other \nviolation of ERISA. \nThe sale of an Interest to a Plan is in no respect a representation by the Fund, the General Partner or \nany other person associated with the offering of Interests that such an investment meets all relevant \nlegal requirements with respect to investments by Plans generally or any particular Plan, or that such \nan investment is appropriate for Plans generally or any particular Plan. \nForm 5500. Plan administrators of ERISA Plans that acquire an Interest in the Fund may be required \nto report compensation, including indirect compensation\n... [truncated, 2502 chars — for the full page use /api/corpus/document/EFTA00617635/67 or ?id=EFTA00617635&page=67]", "char_count": 2502}, {"efta_number": "EFTA00617635", "page_number": 68, "text_content": "IX. ADDITIONAL INFORMATION \nPrior to the consummation of the offering, the General Partner will provide to each investor \nand such investors' representatives and advisers, if any, the opportunity to ask questions and receive \nanswers concerning the terms and conditions of this offering and to obtain additional information \nwhich the General Partner may possess or can obtain without unreasonable effort or expense that is \nnecessary to verify the accuracy of the information furnished to such prospective investor. Any such \nquestion should be directed to: \nMr. Boris Nikolic \n1107 1st Avenue, Apt. 1305 \nSeattle, WA 98101 \n(425) 503-9166 \nSTRICTLY CONFIDENTIAL \n64 \nDRAFT - Jeffery Epstein \nEFTA00617703\n", "char_count": 707}, {"efta_number": "EFTA00617635", "page_number": 69, "text_content": "Appendix A — Certain Securities Law Matters for Investors \nNOTICE TO RESIDENTS OF BRAZIL \nTHIS PRIVATE PLACEMENT HAS NOT BEEN AND WILL NOT BE REGISTERED WITH \nTHE \"COMISSAO DE VALORES MOBILL&RIOS\" (THE BRAZILIAN SECURITIES \nCOMMISSION). THE INTERESTS MAY NOT BE OFFERED OR SOLD IN THE FEDERATIVE \nREPUBLIC OF BRAZIL EXCEPT IN CIRCUMSTANCES THAT DO NOT CONSTITUTE A \nPUBLIC OFFERING OR DISTRIBUTION OF SECURITIES UNDER BRAZILIAN LAWS AND \nREGULATIONS. THIS MEMORANDUM MAY NOT BE REPRODUCED OR USED FOR ANY \nPURPOSE OTHER THAN THIS PRIVATE PLACEMENT, NOR PROVIDED TO ANY OTHER \nPERSON OTHER THAN THE RECIPIENT. \nNOTICE TO RESIDENTS OF LUXEMBOURG \nTHIS MEMORANDUM DOES NOT CONSTITUTE A PUBLIC OFFER OR SOLICITATION IN \nLUXEMBOURG AND ACCORDINGLY SHOULD NOT BE CONSTRUED AS SUCH. AS A \nRESULT, THE LUXEMBOURG REGULATORY AUTHORITIES HAVE NEITHER REVIEWED \nNOR APPROVED THIS MEMORANDUM. NEITHER THIS MEMORANDUM NOR ANY \nFORM OF APPLICATION, ADVERTISEMENT OR OTHER MATERIAL MAY BE \nDISTRIBUTED OR OTHERWISE MADE AVAILABLE TO THE PUBLIC IN OR FROM, OR \nPUBLISHED IN THE GRAND DUCHY OF LUXEMBOURG EXCEPT IN CIRCUMSTANCES \nWHICH DO NOT CONSTITUTE A PUBLIC OFFER. TO THE EXTENT THIS MEMORANDUM \nIS CIRCULATED IN LUXEMBOURG, IT IS TO BE CONSIDERED AS USED IN RELATION \nTO A PRIVATE PLACEMENT ONLY. \nTHE INFORMATION CONTAINED IN THIS MEMORANDUM IS RESTRICTED TO \nSOPHISTICATED OR INSTITUTIONAL INVESTORS. IT IS PERSONAL TO EACH SUCH \nPERSON AND DOES NOT CONSTITUTE AN OFFER TO ANY OTHER PERSON OR TO THE \nPUBLIC GENERALLY TO SUBSCRIBE FOR OR OTHERWISE ACQUIRE THE INTERESTS. \nDISTRIBUTION OF THIS MEMORANDUM OR OF THE INFORMATION CONTAINED IN \nTHIS MEMORANDUM TO ANY PERSON OTHER THAN SOPHISTICATED OR \nINSTITUTIONAL INVESTORS IS UNAUTHORIZED AND ANY DISCLOSURE OF ANY OF \nITS CONTENTS, WITHOUT THE PRIOR WRITTEN CONSENT OF THE PARTNERSHIP IS \nPROHIBITED. \nNOTICE TO RESIDENTS OF MEXICO \nTHIS OFFER HAS NOT BEEN REVIEWED OR APPROVED BY THE MEXICAN BANKING \nAND SECURITIES COMMISSION (COMISION NACIONAL BANCARIA Y \n... [truncated, 2498 chars — for the full page use /api/corpus/document/EFTA00617635/69 or ?id=EFTA00617635&page=69]", "char_count": 2498}, {"efta_number": "EFTA00617635", "page_number": 70, "text_content": "PARTICIPANTS (DISPOSICIONES DE CARACTER GENERAL APL !CABLES A LAS EMISORAS \nDE VALORES Y A OTROS PARTICIPANTES DEL MERCADO DE VALORES) PUBLISHED IN THE \nFEDERAL OFFICIAL GAZETTE ON MARCH 19, 2003 (AS AMENDED). IF YOU DO NOT \nQUALIFY IN EITHER (I) OR (II) ABOVE, YOU SHOULD NOT ACT OR RELY ON THIS OFFER \nTO SELL SECURITIES OR ANY OF ITS CONTENTS. PLEASE NOTE THAT ACTING OR \nRELYING ON ITS CONTENTS SHALL BE DEEMED AS A CONFIRMATION OF YOUR \nREPRESENTATION THAT YOU QUALIFY IN EITHER (I) OR (II) ABOVE. \nNOTICE TO RESIDENTS OF SWITZERLAND \nNONE OF THE PARTNERSHIP, THE GENERAL PARTNER OR THE INVESTMENT ADVISER \nHAS BEEN LICENSED BY THE SWISS FINANCIAL MARKET SUPERVISORY AUTHORITY \n(THE \"FINMA\") FOR DISTRIBUTION TO NON-QUALIFIED INVESTORS PURSUANT TO \nARTICLE 120 PARA. 1 TO 3 OF THE SWISS FEDERAL ACT ON COLLECTIVE INVESTMENT \nSCHEMES OF 23 JUNE 2006, AS AMENDED (\"CISA\"). ACCORDINGLY, PURSUANT TO \nARTICLE 120 PARA. 4 CISA, THE INTERESTS MAY ONLY BE OFFERED AND THIS \nMEMORANDUM MAY ONLY BE DISTRIBUTED IN OR FROM SWITZERLAND TO \nQUALIFIED INVESTORS AS DEFINED IN THE CISA AND ITS IMPLEMENTING \nORDINANCE. FURTHER, THE INTERESTS MAY BE SOLD UNDER THE EXEMPTIONS OF \nARTICLE 3 PARA. 2 CISA. INVESTORS IN THE INTERESTS DO NOT BENEFIT FROM THE \nSPECIFIC INVESTOR PROTECTION PROVIDED BY CISA AND THE SUPERVISION BY THE \nFINMA IN CONNECTION WITH THE LICENSING FOR DISTRIBUTION. \nTHE INTERESTS ARE NOT PUBLICLY OFFERED WITHIN THE MEANING OF ARTICLE \n652A OF THE SWISS CODE OF OBLIGATIONS. AS A CONSEQUENCE, THIS \nMEMORANDUM IS NOT A PROSPECTUS WITHIN THE MEANING OF THIS PROVISION \nAND MAY THEREFORE NOT COMPLY WITH THE INFORMATION STANDARDS \nREQUIRED THEREUNDER. THIS MEMORANDUM IS NOT A LISTING PROSPECTUS \nACCORDING TO ARTICLE 27 ET SEQ. OF THE LISTING RULES OF THE SIX SWISS \nEXCHANGE AND MAY THEREFORE NOT COMPLY WITH THE INFORMATION \nSTANDARDS REQUIRED THEREUNDER OR UNDER THE LISTING RULES OF ANY OTHER \nSWISS STOCK EXCHANGE. \nNOTICE TO RESIDENTS OF THE UNITED KINGDOM \nTHE PARTNERSHIP IS AN UNR\n... [truncated, 2537 chars — for the full page use /api/corpus/document/EFTA00617635/70 or ?id=EFTA00617635&page=70]", "char_count": 2537}, {"efta_number": "EFTA00617635", "page_number": 71, "text_content": "OTHER PERSONS. THIS MEMORANDUM MAY NOT BE CIRCULATED TO ANY PERSON \nWITHOUT THE CONSENT OF THE GENERAL PARTNER. \nNOTICE TO RESIDENTS OF THE UNITED STATES OF AMERICA \nTHE LIMITED PARTNERSHIP INTERESTS IN THE FUND OFFERED HEREBY (THE \n\"INTERESTS\") HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, \nAS AMENDED (THE \"SECURITIES ACT\"), AND MAY NOT BE OFFERED OR SOLD IN THE \nU.S. OR TO \"U.S. PERSONS\" (AS DEFINED IN REGULATION S UNDER THE SECURITIES \nACT) UNLESS REGISTERED UNDER THE SECURITIES ACT OR AN EXEMPTION FROM \nTHE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IS AVAILABLE. \nHEDGING TRANSACTIONS INVOLVING THE INTERESTS MAY NOT BE CONDUCTED \nUNLESS IN COMPLIANCE WITH THE SECURITIES ACT. \nYOU SHOULD MAKE YOUR OWN DECISION AS TO WHETHER THIS OFFERING MEETS \nYOUR INVESTMENT OBJECTIVES AND RISK TOLERANCE LEVEL. NO FEDERAL OR \nSTATE SECURITIES COMMISSION HAS APPROVED, DISAPPROVED, ENDORSED, OR \nRECOMMENDED THIS OFFERING. NO INDEPENDENT PERSON HAS CONFIRMED THE \nACCURACY OR TRUTHFULNESS OF THIS DISCLOSURE, NOR WHETHER IT IS \nCOMPLETE. ANY REPRESENTATION TO THE CONTRARY IS ILLEGAL. \nNO STATE ADMINISTRATOR HAS REVIEWED THIS DISCLOSURE. \nTHE ISSUER IS \nRELYING ON AN EXEMPTION FROM REGISTRATION OR QUALIFICATION. INVESTORS \nMAY BE REQUIRED TO HOLD THE INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. \nOTHER IMPORTANT RISK FACTORS ARE EXPLAINED IN DETAIL IN THIS DOCUMENT. \nTHE NATURE OF THE OFFERING'S RISK REQUIRES THAT INVESTORS MEET MINIMUM \nASSET/INCOME CONDITIONS. \nFOR FLORIDA RESIDENTS ONLY: \nTHE SECURITIES BEING OFFERED HAVE NOT BEEN REGISTERED WITH THE FLORIDA \nDIVISION OF SECURITIES. IF SALES ARE MADE TO FIVE OR MORE FLORIDA \nPURCHASERS, EACH SUCH SALE IS VOIDABLE BY THE PURCHASER WITHIN THREE \nDAYS AFTER THE FIRST TENDER OF CONSIDERATION IS MADE BY SUCH PURCHASER \nTO THE ISSUER, AN AGENT OF THE ISSUER OR AN ESCROW AGENT. OR WITHIN THREE \nDAYS AFTER AVAILABILITY OF THAT PRIVILEGE IS COMMUNICATED TO SUCH \nPURCHASER, WHICHEVER OCCURS LATER. \nFOR NEW HAMPSHIRE RE\n... [truncated, 2587 chars — for the full page use /api/corpus/document/EFTA00617635/71 or ?id=EFTA00617635&page=71]", "char_count": 2587}, {"efta_number": "EFTA00617635", "page_number": 72, "text_content": "MEANS THAT THE NEW HAMPSHIRE SECRETARY OF STATE HAS PASSED IN ANY WAY \nUPON THE MERITS OR QUALIFICATIONS OF, OR RECOMMENDED OR GIVEN APPROVAL \nTO, ANY PERSON, SECURITY, OR TRANSACTION. IT IS UNLAWFUL TO MAKE, OR \nCAUSE TO BE MADE, TO ANY PROSPECTIVE PURCHASER, CUSTOMER, OR CLIENT ANY \nREPRESENTATION INCONSISTENT WITH THE PROVISIONS OF THIS PARAGRAPH. \nPRIVACY NOTICE TO U.S. INVESTORS \nIN THE NORMAL COURSE OF ITS FORMATION, OPERATION AND DISSOLUTION, THE \nFUND WILL COLLECT AND DISCLOSE CERTAIN PRIVATE INFORMATION ABOUT ITS \nLIMITED PARTNERS. PERSONAL FINANCIAL INFORMATION ABOUT THE LIMITED \nPARTNERS, SUCH AS THEIR NAMES, ADDRESSES, SOCIAL SECURITY NUMBERS, \nASSETS AND INCOMES, WILL BE OBTAINED FROM SUBSCRIPTION AGREEMENTS AND \nOTHER DOCUMENTS. \nOTHER PERSONAL INFORMATION ABOUT THE LIMITED \nPARTNERS, SUCH AS CAPITAL ACCOUNT BALANCES, ACCOUNT DATA AND \nINFORMATION ABOUT THEIR PARTICIPATION IN OTHER INVESTMENTS, WILL BE \nOBTAINED IN THE COURSE OF TRANSACTIONS BETWEEN THE LIMITED PARTNERS \nAND THE FUND OR ITS AFFILIATES. \nEXCEPT AS DESCRIBED BELOW, THIS PRIVATE INFORMATION WILL BE DISCLOSED \nONLY AS PERMITTED BY APPLICABLE LAW TO THE FUND'S AFFILIATES AND SERVICE \nPROVIDERS, INCLUDING THE FUND'S ACCOUNTANTS, ATTORNEYS, BROKER-\nDEALERS, CUSTODIANS, TRANSFER AGENTS, AND ANY OTHER PARTIES WHOSE \nSERVICES ARE NECESSARY OR CONVENIENT TO THE FORMATION, OPERATION OR \nDISSOLUTION OF THE FUND. ANY PARTY RECEIVING PRIVATE INFORMATION ABOUT \nTHE LIMITED PARTNERS PURSUANT TO THE PRECEDING SENTENCE WILL BE \nAUTHORIZED TO USE SUCH INFORMATION ONLY TO PERFORM THE SERVICES \nREQUIRED AND AS PERMITTED BY APPLICABLE LAW. NO PARTY RECEIVING A \nLIMITED PARTNER'S PERSONAL INFORMATION WILL BE AUTHORIZED TO USE OR \nSHARE THAT INFORMATION FOR ANY OTHER PURPOSE. \nWITH RESPECT TO PERSONNEL OF THE FUND AND ITS AFFILIATES, ACCESS TO \nPRIVATE INFORMATION ABOUT THE LIMITED PARTNERS WILL BE RESTRICTED TO \nINDIVIDUALS WHO REQUIRE SUCH ACCESS TO PROVIDE SERVICES TO THE FUND AND \nTHE LIMITED PARTNERS. THE\n... [truncated, 2613 chars — for the full page use /api/corpus/document/EFTA00617635/72 or ?id=EFTA00617635&page=72]", "char_count": 2613}, {"efta_number": "EFTA00617635", "page_number": 73, "text_content": "FOR OTHER PROSPECTIVE NON-U.S. INVESTORS \nOTHER PROSPECTIVE NON-U.S. INVESTORS SHOULD INFORM THEMSELVES AS TO THE \nLEGAL REQUIREMENTS AND TAX CONSEQUENCES WITHIN THE COUNTRIES OF THEIR \nCITIZENSHIP, RESIDENCE, DOMICILE AND PLACE OF BUSINESS WITH RESPECT TO THE \nACQUISITION, HOLDING OR DISPOSAL OF THE INTERESTS, AND ANY FOREIGN \nEXCHANGE RESTRICTIONS THAT MAY BE RELEVANT THERETO. IT IS THE \nRESPONSIBILITY OF ANY INVESTOR WISHING TO PURCHASE INTERESTS TO SATISFY \nITSELF AS TO THE FULL OBSERVANCE OF THE LAWS OF ANY RELEVANT TERRITORY \nOUTSIDE THE UNITED STATES IN CONNECTION WITH SUCH PURCHASE, INCLUDING \nTHE PROCUREMENT OF ANY REQUIRED GOVERNMENTAL OR OTHER CONSENTS AND \nTHE OBSERVATION OF ANY OTHER APPLICABLE FORMALITIES. THIS MEMORANDUM \nDOES NOT CONSTITUTE AN OFFER TO OR SOLICITATION OF ANYONE IN ANY \nJURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION IS NOT AUTHORIZED. \nSTRICTLY CONFIDENTIAL \n69 \nDRAFT - Jeffery Epstein \nEFTA00617708\n", "char_count": 950}]}